Epigenetics of prostate cancer: beyond DNA methylation

W A Schulz; J Hatina

doi:10.1111/j.1582-4934.2006.tb00293.x

. 2007 Mar 15;10(1):100–125. doi: 10.1111/j.1582-4934.2006.tb00293.x

Epigenetics of prostate cancer: beyond DNA methylation

W A Schulz ^1,^*, J Hatina ¹

PMCID: PMC3933104 PMID: 16563224

Abstract

Epigenetic mechanisms permit the stable inheritance of cellular properties without changes in DNA sequence or amount. In prostate carcinoma, epigenetic mechanisms are essential for development and progression, complementing, amplifying and diversifying genetic alterations. DNA hypermethylation affects at least 30 individual genes, while repetitive sequences including retrotransposons and selected genes become hypomethylated. Hypermethylation of several genes occurs in a coordinate manner early in carcinogenesis and can be exploited for cancer detection, whereas hypomethylation and further hypermethylation events are associated with progression. DNA methylation alterations interact with changes in chromatin proteins. Prominent alterations at this level include altered patterns of histone modification, increased expression of the EZH2 polycomb histone methyltransferase, and changes in transcriptional corepressors and coactivators. These changes may make prostate carcinoma particularly susceptible to drugs targeting chromatin and DNA modifications. They relate to crucial alterations in a network of transcription factors comprising ETS family proteins, the androgen receptor, NKX3.1, KLF, and HOXB13 homeobox proteins. This network controls differentiation and proliferation of prostate epithelial cells integrating signals from hormones, growth factors and cell adhesion proteins that are likewise distorted in prostate cancer. As a consequence, prostate carcinoma cells appear to be locked into an aberrant state, characterized by continued proliferation of largely differentiated cells. Accordingly, stem cell characteristics of prostate cancer cells appear to be secondarily acquired. The aberrant differentiation state of prostate carcinoma cells also results in distorted mutual interactions between epithelial and stromal cells in the tumor that promote tumor growth, invasion, and metastasis.

Keywords: DNA methylation, chromatin, transcription factor, tumor suppressor, prostate carcinoma, growth factor, tumor stroma, androgen receptor coactivator, cancer stem cell

References

1.Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970–2002. JAMA. 2005;294:1255–9. doi: 10.1001/jama.294.10.1255. [DOI] [PubMed] [Google Scholar]
2.Schalken JA, Bergh A, Bono A, Foster C, Gospadarowicz M, Isaacs WB, Rubin M, Schroder F, Tribukait B, Tsukamotot T, Wiklund P. Molecular prostate cancer pathology: current issues and achievements. Scand J Urol Nephrol Suppl. 2005:82–93. doi: 10.1080/03008880510030950. [DOI] [PubMed] [Google Scholar]
3.Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J, Morrison H, Sonawane B, Shifflett T, Waters DJ, Timms B. Human prostate cancer risk factors. Cancer. 2004;101:2371–490. doi: 10.1002/cncr.20408. [DOI] [PubMed] [Google Scholar]
4.Bratt O. Hereditary prostate cancer: clinical aspects. J Urol. 2002;168:906–13. doi: 10.1016/S0022-5347(05)64541-7. [DOI] [PubMed] [Google Scholar]
5.Simard J, Dumont M, Soucy P, Labrie F. Perspective: prostate cancer susceptibility genes. Endocrinology. 2002;143:2029–40. doi: 10.1210/endo.143.6.8890. [DOI] [PubMed] [Google Scholar]
6.Silverman RH. Implications for RNase L in prostate cancer biology. Biochemistry. 2003;42:1805–12. doi: 10.1021/bi027147i. [DOI] [PubMed] [Google Scholar]
7.Nelson WG, de Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med. 2003;349:366–81. doi: 10.1056/NEJMra021562. [DOI] [PubMed] [Google Scholar]
8.Andriole G, Bostwick D, Civantos F, Epstein J, Lucia MS, McConnell J, Roehrborn CG. The effects of 5α-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge. J Urol. 2005;174:2098–104. doi: 10.1097/01.ju.0000181216.71605.38. [DOI] [PubMed] [Google Scholar]
9.Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001;1:34–45. doi: 10.1038/35094009. [DOI] [PubMed] [Google Scholar]
10.Jarrard DF, Kinoshita H, Shi Y, Sandefur C, Hoff D, Meisner LF, Chang C, Herman JG, Isaacs WB, Nassif N. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer Res. 1998;58:5310–4. [PubMed] [Google Scholar]
11.Dong JT. Chromosomal deletions and tumor suppressor genes in prostate cancer. Cancer Metastasis Rev. 2001;20:173–93. doi: 10.1023/a:1015575125780. [DOI] [PubMed] [Google Scholar]
12.Schulz WA, Burchardt M, Cronauer MV. Molecular biology of prostate cancer. Mol Hum Reprod. 2003;9:437–48. doi: 10.1093/molehr/gag064. [DOI] [PubMed] [Google Scholar]
13.Porkka KP, Visakorpi T. Molecular mechanisms of prostate cancer. Eur Urol. 2004;45:683–91. doi: 10.1016/j.eururo.2004.01.012. [DOI] [PubMed] [Google Scholar]
14.Kindich R, Florl AR, Kamradt J, Lehmann J, Müller M, Wullich B, Schulz WA. Relationship of NKX3.1 and MYC gene copy number ratio and DNA hypomethylation to prostate carcinoma stage. Eur Urol. 2006;49:169–75. doi: 10.1016/j.eururo.2005.09.012. [DOI] [PubMed] [Google Scholar]
15.Nakayama M, Gonzalgo ML, Yegnasubramanian S, Lin X, de Marzo AM, Nelson WG. GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J Cell Biochem. 2004;91:540–52. doi: 10.1002/jcb.10740. [DOI] [PubMed] [Google Scholar]
16.Holliday R. Epigenetics: an overview. Dev Genet. 1994;15:453–7. doi: 10.1002/dvg.1020150602. [DOI] [PubMed] [Google Scholar]
17.Slack JM. Conrad Hal Waddington: the last Renaissance biologist. Nat Rev Genet. 2002;3:889–95. doi: 10.1038/nrg933. [DOI] [PubMed] [Google Scholar]
18.de Ininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96:3343–56. [PubMed] [Google Scholar]
19.Jarrard DF, Bussemakers MJ, Bova GS, Isaacs WB. Regional loss of imprinting of the insulin-like growth factor II gene occurs in human prostate tissues. Clin Cancer Res. 1995;1:1471–8. [PubMed] [Google Scholar]
20.Florl AR, Steinhoff C, Muller M, Seifert HH, Hader C, Engers R, Ackermann R, Schulz WA. Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. Br J Cancer. 2004;91:985–994. doi: 10.1038/sj.bjc.6602030. [DOI] [PMC free article] [PubMed] [Google Scholar]
21.Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, Bova GS, de Marzo AM, Isaacs WB, Nelson WG. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res. 2004;64:1975–86. doi: 10.1158/0008-5472.can-03-3972. [DOI] [PubMed] [Google Scholar]
22.Cookson MS, Reuter VE, Linkov I, Fair WR. Glutathione S-transferase PI (GST-pi) class expression by immunohistochemistry in benign and malignant prostate tissue. J Urol. 1997;157:673–6. [PubMed] [Google Scholar]
23.Nakayama T, Watanabe M, Yamanaka M, Hirokawa Y, Suzuki H, Ito H, Yatani R, Shiraishi T. The role of epigenetic modifications in retinoic acid receptor β2 gene expression in human prostate cancers. Lab Invest. 2001;81:1049–57. doi: 10.1038/labinvest.3780316. [DOI] [PubMed] [Google Scholar]
24.Dammann R, Schagdarsurengin U, Seidel C, Strunnikova M, Rastetter M, Baier K, Pfeifer GP. The tumor suppressor RASSF1A in human carcinogenesis: an update. Histol Histopathol. 2005;20:645–63. doi: 10.14670/HH-20.645. [DOI] [PubMed] [Google Scholar]
25.Tsuchiya T, Tamura G, Sato K, Endoh Y, Sakata K, Jin Z, Motoyama T, Usuba O, Kimura W, Nishizuka S, Wilson KT, James SP, Yin J, Fleisher AS, Zou T, Silverberg SG, Kong D, Meltzer SJ. Distinct methylation patterns of two APC gene promoters in normal and cancerous gastric epithelia. Oncogene. 2000;19:3642–6. doi: 10.1038/sj.onc.1203704. [DOI] [PubMed] [Google Scholar]
26.Santourlidis S, Florl A, Ackermann R, Wirtz HC, Schulz WA. High frequency of alterations in DNA methylation in adenocarcinoma of the prostate. Prostate. 1999;39:166–74. doi: 10.1002/(sici)1097-0045(19990515)39:3<166::aid-pros4>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
27.Tokizane T, Shiina H, Igawa M, Enokida H, Urakami S, Kawakami T, Ogishima T, Okino ST, Li LC, Tanaka Y, Nonomura N, Okuyama A, Dahiya R. Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer. Clin Cancer Res. 2005;11:5793–801. doi: 10.1158/1078-0432.CCR-04-2545. [DOI] [PubMed] [Google Scholar]
28.Ogishima T, Shiina H, Breault JE, Tabatabai L, Bassett WW, Enokida H, Li LC, Kawakami T, Urakami S, Ribeiro-Filho LA, Terashima M, Fujime M, Igawa M, Dahiya R. Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer. Clin Cancer Res. 2005;11:1028–36. [PubMed] [Google Scholar]
29.Laner T, Schulz WA, Engers R, Muller M, Florl AR. Hypomethylation of the XIST gene promoter in prostate cancer. Oncol Res. 2005;15:257–64. doi: 10.3727/096504005776404607. [DOI] [PubMed] [Google Scholar]
30.Hoffmann MJ, Schulz WA. Causes and consequences of DNA hypomethylation in human cancer. Biochem Cell Biol. 2005;83:296–321. doi: 10.1139/o05-036. [DOI] [PubMed] [Google Scholar]
31.Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3:415–28. doi: 10.1038/nrg816. [DOI] [PubMed] [Google Scholar]
32.Ballestar E, Esteller M. Methyl-CpG-binding proteins in cancer: blaming the DNA methylation messenger. Biochem Cell Biol. 2005;83:374–84. doi: 10.1139/o05-035. [DOI] [PubMed] [Google Scholar]
33.Robertson KD. DNA methylation and human disease. Nat Rev Genet. 2005;6:597–610. doi: 10.1038/nrg1655. [DOI] [PubMed] [Google Scholar]
34.Santoro R, de Lucia F. Many players, one goal: how chromatin states are inherited during cell division. Biochem Cell Biol. 2005;83:332–343. doi: 10.1139/o05-021. [DOI] [PubMed] [Google Scholar]
35.Patra SK, Patra A, Zhao H, Carroll P, Dahiya R. Methyl-CpG-DNA binding proteins in human prostate cancer: expression of CXXC sequence containing MBD1 and repression of MBD2 and MeCP2. Biochem Biophys Res Commun. 2003;302:759–66. doi: 10.1016/s0006-291x(03)00253-5. [DOI] [PubMed] [Google Scholar]
36.Freitag M, Selker EU. Controlling DNA methylation: many roads to one modification. Curr Opin Genet Dev. 2005;15:191–9. doi: 10.1016/j.gde.2005.02.003. [DOI] [PubMed] [Google Scholar]
37.Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002;419:624–9. doi: 10.1038/nature01075. [DOI] [PubMed] [Google Scholar]
38.Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J. 2003;22:5323–35. doi: 10.1093/emboj/cdg542. [DOI] [PMC free article] [PubMed] [Google Scholar]
39.Tang X, Milyavsky M, Shats I, Erez N, Goldfinger N, Rotter V. Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene. 2004;23:5759–69. doi: 10.1038/sj.onc.1207706. [DOI] [PubMed] [Google Scholar]
40.Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, Kurdistani SK. Global histone modification patterns predict risk of prostate cancer recurrence. Nature. 2005;435:1262–1266. doi: 10.1038/nature03672. [DOI] [PubMed] [Google Scholar]
41.Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K, Iyer NG, Perez-Rosado A, Calvo E, Lopez JA, Cano A, Calasanz MJ, Colomer D, Piris MA, Ahn N, Imhof A, Caldas C, Jenuwein T, Esteller M. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet. 2005;37:391–400. doi: 10.1038/ng1531. [DOI] [PubMed] [Google Scholar]
42.Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, Casero RA, Shi Y. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 2004;119:941–53. doi: 10.1016/j.cell.2004.12.012. [DOI] [PubMed] [Google Scholar]
43.Metzger E, Wissmann M, Yin N, Muller JM, Schneider R, Peters AH, Gunther T, Buettner R, Schule R. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature. 2005;437:436–9. doi: 10.1038/nature04020. [DOI] [PubMed] [Google Scholar]
44.Knossl M, Lower R, Lower J. Expression of the human endogenous retrovirus HTDV/ HERV-K is enhanced by cellular transcription factor YY1. J Virol. 1999;73:1254–61. doi: 10.1128/jvi.73.2.1254-1261.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
45.Seligson D, Horvath S, Huerta-Yepez S, Hanna S, Garban H, Roberts A, Shi T, Liu X, Chia D, Goodglick L, Bonavida B. Expression of transcription factor Yin Yang 1 in prostate cancer. Int J Oncol. 2005;27:131–41. [PubMed] [Google Scholar]
46.Schulz WA, Elo JP, Florl AR, Pennanen S, Santourlidis S, Engers R, Buchardt M, Seifert HH, Visakorpi T. Genomewide DNA hypomethylation is associated with alterations on chromosome 8 in prostate carcinoma. Genes Chromosomes Cancer. 2002;35:58–65. doi: 10.1002/gcc.10092. [DOI] [PubMed] [Google Scholar]
47.Klenova EM, Morse HC, III, Ohlsson R, Lobanenkov VV. The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer. Semin Cancer Biol. 2002;12:399–414. doi: 10.1016/s1044-579x(02)00060-3. [DOI] [PubMed] [Google Scholar]
48.Leman ES, Madigan MC, Brunagel G, Takaha N, Coffey DS, Getzenberg RH. Nuclear matrix localization of high mobility group protein I(Y) in a transgenic mouse model for prostate cancer. J Cell Biochem. 2003;88:599–608. doi: 10.1002/jcb.10368. [DOI] [PubMed] [Google Scholar]
49.Takaha N, Hawkins AL, Griffin CA, Isaacs WB, Coffey DS. High mobility group protein I(Y): a candidate architectural protein for chromosomal rearrangements in prostate cancer cells. Cancer Res. 2002;62:647–51. [PubMed] [Google Scholar]
50.Hofer MD, Kuefer R, Varambally S, Li H, Ma J, Shapiro GI, Gschwend JE, Hautmann RE, Sanda MG, Giehl K, Menke A, Chinnaiyan AM, Rubin MA. The role of metastasis-associated protein 1 in prostate cancer progression. Cancer Res. 2004;64:825–9. doi: 10.1158/0008-5472.can-03-2755. [DOI] [PubMed] [Google Scholar]
51.Li LC, Carroll PR, Dahiya R. Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst. 2005;97:103–15. doi: 10.1093/jnci/dji010. [DOI] [PubMed] [Google Scholar]
52.Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol. 2005;45:495–528. doi: 10.1146/annurev.pharmtox.45.120403.095825. [DOI] [PubMed] [Google Scholar]
53.Lyko F, Brown R. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst. 2005;97:1498–506. doi: 10.1093/jnci/dji311. [DOI] [PubMed] [Google Scholar]
54.Cronauer MV, Schulz WA, Burchardt T, Anastasiadis AG, de La TA, Ackermann R, Burchardt M. The androgen receptor in hormonerefractory prostate cancer: relevance of different mechanisms of androgen receptor signaling (Review) Int J Oncol. 2003;23:1095–102. doi: 10.3892/ijo.23.4.1095. [DOI] [PubMed] [Google Scholar]
55.Culig Z, Comuzzi B, Steiner H, Bartsch G, Hobisch A. Expression and function of androgen receptor coactivators in prostate cancer. J Steroid Biochem Mol Biol. 2004;92:265–71. doi: 10.1016/j.jsbmb.2004.10.003. [DOI] [PubMed] [Google Scholar]
56.Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev. 2004;25:276–308. doi: 10.1210/er.2002-0032. [DOI] [PubMed] [Google Scholar]
57.Linja MJ, Visakorpi T. Alterations of androgen receptor in prostate cancer. J Steroid Biochem Mol Biol. 2004;92:255–64. doi: 10.1016/j.jsbmb.2004.10.012. [DOI] [PubMed] [Google Scholar]
58.Yang Y, Hou H, Haller EM, Nicosia SV, Bai W. Suppression of FOXO1 activity by FHL2 through SIRT1-mediated deacetylation. EMBO J. 2005;24:1021–32. doi: 10.1038/sj.emboj.7600570. [DOI] [PMC free article] [PubMed] [Google Scholar]
59.Khanim FL, Gommersall LM, Wood VH, Smith KL, Montalvo L, O'Neill LP, Xu Y, Peehl DM, Stewart PM, Turner BM, Campbell MJ. Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells. Oncogene. 2004;23:6712–25. doi: 10.1038/sj.onc.1207772. [DOI] [PubMed] [Google Scholar]
60.Chua SS, Ma Z, Ngan E, Tsai SY. Cdc25B as a steroid receptor coactivator. Vitam Horm. 2004;68:231–56. doi: 10.1016/S0083-6729(04)68008-3. [DOI] [PubMed] [Google Scholar]
61.Lim JT, Mansukhani M, Weinstein IB. Cyclindependent kinase 6 associates with the androgen receptor and enhances its transcriptional activity in prostate cancer cells. Proc Natl Acad Sci USA. 2005;102:5156–61. doi: 10.1073/pnas.0501203102. [DOI] [PMC free article] [PubMed] [Google Scholar]
62.Petre CE, Wetherill YB, Danielsen M, Knudsen KE. Cyclin D1: mechanism and consequence of androgen receptor co-repressor activity. J Biol Chem. 2002;277:2207–15. doi: 10.1074/jbc.M106399200. [DOI] [PubMed] [Google Scholar]
63.Zwijsen RM, Wientjens E, Klompmaker R, Van de Ran SJ, Bernards R, Michalides RJ. CDK-independent activation of estrogen receptor by cyclin D1. Cell. 1997;88:405–15. doi: 10.1016/s0092-8674(00)81879-6. [DOI] [PubMed] [Google Scholar]
64.Knudsen KE, Arden KC, Cavenee WK. Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells. J Biol Chem. 1998;273:20213–22. doi: 10.1074/jbc.273.32.20213. [DOI] [PubMed] [Google Scholar]
65.Han EK, Lim JT, Arber N, Rubin MA, Xing WQ, Weinstein IB. Cyclin D1 expression in human prostate carcinoma cell lines and primary tumors. Prostate. 1998;35:95–101. doi: 10.1002/(sici)1097-0045(19980501)35:2<95::aid-pros2>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
66.Shiraishi T, Watanabe M, Muneyuki T, Nakayama T, Morita J, Ito H, Kotake T, Yatani R. A clinicopathological study of p53, p21 (WAF1/CIP1) and cyclin D1 expression in human prostate cancers. Urol Int. 1998;61:90–4. doi: 10.1159/000030295. [DOI] [PubMed] [Google Scholar]
67.Bernard D, Pourtier-Manzanedo A, Gil J, Beach DH. Myc confers androgen-independent prostate cancer cell growth. J Clin Invest. 2003;112:1724–31. doi: 10.1172/JCI19035. [DOI] [PMC free article] [PubMed] [Google Scholar]
68.Zhang XY, de Salle LM, Patel JH, Capobianco AJ, Yu D, Thomas-Tikhonenko A, McMahon SB. Metastasis-associated protein 1 (MTA1) is an essential downstream effector of the c-MYC oncoprotein. Proc Natl Acad Sci USA. 2005;102:13968–73. doi: 10.1073/pnas.0502330102. [DOI] [PMC free article] [PubMed] [Google Scholar]
69.Savinainen KJ, Linja MJ, Saramaki OR, Tammela TL, Chang GT, Brinkmann AO, Visakorpi T. Expression and copy number analysis of TRPS1, EIF3S3 and MYC genes in breast and prostate cancer. Br J Cancer. 2004;90:1041–6. doi: 10.1038/sj.bjc.6601648. [DOI] [PMC free article] [PubMed] [Google Scholar]
70.Verras M, Sun Z. Roles and regulation of Wnt signaling and β-catenin in prostate cancer. Cancer Lett. 2005 doi: 10.1016/j.canlet.2005.06.004. [DOI] [PubMed] [Google Scholar]
71.Li LC, Okino ST, Dahiya R. DNA methylation in prostate cancer. Biochim Biophys Acta. 2004;1704:87–102. doi: 10.1016/j.bbcan.2004.06.001. [DOI] [PubMed] [Google Scholar]
72.Schulz WA, Seifert HH. DNA methylation in urological cancers. In: Szyf M, editor. DNA methylation and cancer therapy. Landes Biosciences; 2004. pp. 42–58. Georgetown: [Google Scholar]
73.Yang F, Li X, Sharma M, Sasaki CY, Longo DL, Lim B, Sun Z. Linking β-catenin to androgen-signaling pathway. J Biol Chem. 2002;277:11336–44. doi: 10.1074/jbc.M111962200. [DOI] [PubMed] [Google Scholar]
74.Chesire DR, Isaacs WB. Ligand-dependent inhibition of β-catenin/TCF signaling by androgen receptor. Oncogene. 2002;21:8453–69. doi: 10.1038/sj.onc.1206049. [DOI] [PubMed] [Google Scholar]
75.Cronauer MV, Schulz WA, Ackermann R, Burchardt M. Effects of WNT/β-catenin pathway activation on signaling through T-cell factor and androgen receptor in prostate cancer cell lines. Int J Oncol. 2005;26:1033–40. doi: 10.3892/ijo.26.4.1033. [DOI] [PubMed] [Google Scholar]
76.Masiello D, Chen SY, Xu Y, Verhoeven MC, Choi E, Hollenberg AN, Balk SP. Recruitment of β-catenin by wild-type or mutant androgen receptors correlates with ligand-stimulated growth of prostate cancer cells. Mol Endocrinol. 2004;18:2388–401. doi: 10.1210/me.2003-0436. [DOI] [PubMed] [Google Scholar]
77.Amir AL, Barua M, McKnight NC, Cheng S, Yuan X, Balk SP. A direct β-catenin-independent interaction between androgen receptor and T cell factor 4. J Biol Chem. 2003;278:30828–34. doi: 10.1074/jbc.M301208200. [DOI] [PubMed] [Google Scholar]
78.Jung C, Kim RS, Lee SJ, Wang C, Jeng MH. HOXB13 homeodomain protein suppresses the growth of prostate cancer cells by the negative regulation of T-cell factor 4. Cancer Res. 2004;64:3046–51. doi: 10.1158/0008-5472.can-03-2614. [DOI] [PubMed] [Google Scholar]
79.Jung C, Kim RS, Zhang HJ, Lee SJ, Jeng MH. HOXB13 induces growth suppression of prostate cancer cells as a repressor of hormone-activated androgen receptor signaling. Cancer Res. 2004;64:9185–92. doi: 10.1158/0008-5472.CAN-04-1330. [DOI] [PubMed] [Google Scholar]
80.Halkidou K, Gnanapragasam VJ, Mehta PB, Logan IR, Brady ME, Cook S, Leung HY, Neal DE, Robson CN. Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene. 2003;22:2466–77. doi: 10.1038/sj.onc.1206342. [DOI] [PubMed] [Google Scholar]
81.Kim JH, Kim B, Cai L, Choi HJ, Ohgi KA, Tran C, Chen C, Chung CH, Huber O, Rose DW, Sawyers CL, Rosenfeld MG, Baek SH. Transcriptional regulation of a metastasis suppressor gene by Tip60 and β-catenin complexes. Nature. 2005;434:921–6. doi: 10.1038/nature03452. [DOI] [PubMed] [Google Scholar]
82.Dong JT, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT, Barrett JC. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science. 1995;268:884–6. doi: 10.1126/science.7754374. [DOI] [PubMed] [Google Scholar]
83.Marreiros A, Dudgeon K, Dao V, Grimm MO, Czolij R, Crossley M, Jackson P. KAI1 promoter activity is dependent on p53, junB and AP2: evidence for a possible mechanism underlying loss of KAI1 expression in cancer cells. Oncogene. 2005;24:637–49. doi: 10.1038/sj.onc.1208216. [DOI] [PubMed] [Google Scholar]
84.Shen MM, Abate-Shen C. Roles of the Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis. Dev Dyn. 2003;228:767–78. doi: 10.1002/dvdy.10397. [DOI] [PubMed] [Google Scholar]
85.Kim MJ, Cardiff RD, de Sai N, Banach-Petrosky WA, Parsons R, Shen MM, Abate-Shen C. Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci USA. 2002;99:2884–9. doi: 10.1073/pnas.042688999. [DOI] [PMC free article] [PubMed] [Google Scholar]
86.Abate-Shen C, Banach-Petrosky WA, Sun X, Economides KD, de Sai N, Gregg JP, Borowsky AD, Cardiff RD, Shen MM. Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. Cancer Res. 2003;63:3886–90. [PubMed] [Google Scholar]
87.Gao H, Ouyang X, Banach-Petrosky W, Borowsky AD, Lin Y, Kim M, Lee H, Shih WJ, Cardiff RD, Shen MM, Abate-Shen C. A critical role for p27kip1 gene dosage in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci USA. 2004;101:17204–9. doi: 10.1073/pnas.0407693101. [DOI] [PMC free article] [PubMed] [Google Scholar]
88.Bhatia-Gaur R, Donjacour AA, Sciavolino PJ, Kim M, de Sai N, Young P, Norton CR, Gridley T, Cardiff RD, Cunha GR, Abate-Shen C, Shen MM. Roles for Nkx3.1 in prostate development and cancer. Genes Dev. 1999;13:966–77. doi: 10.1101/gad.13.8.966. [DOI] [PMC free article] [PubMed] [Google Scholar]
89.Asatiani E, Huang WX, Wang A, Rodriguez OE, Cavalli LR, Haddad BR, Gelmann EP. Deletion, methylation, and expression of the NKX3.1 suppressor gene in primary human prostate cancer. Cancer Res. 2005;65:1164–73. doi: 10.1158/0008-5472.CAN-04-2688. [DOI] [PubMed] [Google Scholar]
90.Magee JA, Abdulkadir SA, Milbrandt J. Haploinsufficiency at the Nkx3.1 locus. A paradigm for stochastic, dosage-sensitive gene regulation during tumor initiation. Cancer Cell. 2003;3:273–283. doi: 10.1016/s1535-6108(03)00047-3. [DOI] [PubMed] [Google Scholar]
91.Trotman LC, Niki M, Dotan ZA, Koutcher JA, Von Cristofano A, Xiao A, Khoo AS, Roy-Burman P, Greenberg NM, Van Dyke T, Cordon-Cardo C, Pandolfi PP. Pten dose dictates cancer progression in the prostate. PLoS Biol. 2003;1:E59. doi: 10.1371/journal.pbio.0000059. [DOI] [PMC free article] [PubMed] [Google Scholar]
92.Tsihlias J, Kapusta LR, de Boer G, Morava-Protzner I, Zbieranowski I, Bhattacharya N, Catzavelos GC, Klotz LH, Slingerland JM. Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res. 1998;58:542–548. [PubMed] [Google Scholar]
93.Yang RM, Naitoh J, Murphy M, Wang HJ, Phillipson J, de Kernion JB, Loda M, Reiter RE. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol. 1998;159:941–945. [PubMed] [Google Scholar]
94.Cordon-Cardo C, Koff A, Drobnjak M, Capodieci P, Osman I, Millard SS, Gaudin PB, Fazzari M, Zhang ZF, Massague J, Scher HI. Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst. 1998;90:1284–1291. doi: 10.1093/jnci/90.17.1284. [DOI] [PubMed] [Google Scholar]
95.Kibel AS, Christopher M, Faith DA, Bova GS, Goodfellow PJ, Isaacs WB. Methylation and mutational analysis of p27(kip1) in prostate carcinoma. Prostate. 2001;48:248–253. doi: 10.1002/pros.1104. [DOI] [PubMed] [Google Scholar]
96.Zeltser L, de Splan C, Heintz N. Hoxb-13: a new Hox gene in a distant region of the HOXB cluster maintains colinearity. Development. 1996;122:2475–2484. doi: 10.1242/dev.122.8.2475. [DOI] [PubMed] [Google Scholar]
97.Economides KD, Capecchi MR. Hoxb13 is required for normal differentiation and secretory function of the ventral prostate. Development. 2003;130:2061–2069. doi: 10.1242/dev.00432. [DOI] [PubMed] [Google Scholar]
98.Dhanasekaran SM, Dash A, Yu J, Maine IP, Laxman B, Tomlins SA, Creighton CJ, Menon A, Rubin MA, Chinnaiyan AM. Molecular profiling of human prostate tissues: insights into gene expression patterns of prostate development during puberty. FASEB J. 2005;19:243–245. doi: 10.1096/fj.04-2415fje. [DOI] [PubMed] [Google Scholar]
99.Jung C, Kim RS, Zhang H, Lee SJ, Sheng H, Loehrer PJ, Gardner TA, Jeng MH, Kao C. HOXB13 is downregulated in colorectal cancer to confer TCF4-mediated transactivation. Br J Cancer. 2005;92:2233–2239. doi: 10.1038/sj.bjc.6602631. [DOI] [PMC free article] [PubMed] [Google Scholar]
100.Edwards S, Campbell C, Flohr P, Shpley J, Giddings I, Te-Poele R, Dodson A, Foster C, Clark J, Jhavar S, Kovacs G, Cooper CS. Expression analysis onto microarrays of randomly selected cDNA clones highlights HOXB13 as a marker of human prostate cancer. Br J Cancer. 2005;92:376–81. doi: 10.1038/sj.bjc.6602261. [DOI] [PMC free article] [PubMed] [Google Scholar]
101.Reid JF, Lusa L, de Cecco L, Coradini D, Veneroni S, Daidone MG, Gariboldi M, Pierotti MA. Limits of predictive models using microarray data for breast cancer clinical treatment outcome. J Natl Cancer Inst. 2005;97:927–30. doi: 10.1093/jnci/dji153. [DOI] [PubMed] [Google Scholar]
102.Narla G, Heath KE, Reeves HL, Li D, Giono LE, Kimmelman AC, Glucksman MJ, Narla J, Eng FJ, Chan AM, Ferrari AC, Martignetti JA, Friedman SL. KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science. 2001;294:2563–6. doi: 10.1126/science.1066326. [DOI] [PubMed] [Google Scholar]
103.Chen C, Hyytinen ER, Sun X, Helin HJ, Koivisto PA, Frierson HF, Jr, Vessella RL, Dong JT. Deletion, mutation, and loss of expression of KLF6 in human prostate cancer. Am J Pathol. 2003;162:1349–54. doi: 10.1016/S0002-9440(10)63930-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
104.Muhlbauer KR, Grone HJ, Ernst T, Grone E, Tschada R, Hergenhahn M, Hollstein M. Analysis of human prostate cancers and cell lines for mutations in the TP53 and KLF6 tumour suppressor genes. Br J Cancer. 2003;89:687–90. doi: 10.1038/sj.bjc.6601164. [DOI] [PMC free article] [PubMed] [Google Scholar]
105.Narla G, Difeo A, Reeves HL, Schaid DJ, Hirshfeld J, Hod E, Katz A, Isaacs WB, Hebbring S, Komiya A, McDonnell SK, Wiley KE, Jacobsen SJ, Isaacs SD, Walsh PC, Zheng SL, Chang BL, Friedrichsen DM, Stanford JL, Ostrander EA, Chinnaiyan AM, Rubin MA, Xu J, Thibodeau SN, Friedman SL, Martignetti JA. A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res. 2005;65:1213–22. doi: 10.1158/0008-5472.CAN-04-4249. [DOI] [PubMed] [Google Scholar]
106.Li D, Yea S, Dolios G, Martignetti JA, Narla G, Wang R, Walsh MJ, Friedman SL. Regulation of Kruppel-like factor 6 tumor suppressor activity by acetylation. Cancer Res. 2005;65:9216–25. doi: 10.1158/0008-5472.CAN-05-1040. [DOI] [PubMed] [Google Scholar]
107.Chen C, Bhalala HV, Vessella RL, Dong JT. KLF5 is frequently deleted and down-regulated but rarely mutated in prostate cancer. Prostate. 2003;55:81–8. doi: 10.1002/pros.10205. [DOI] [PubMed] [Google Scholar]
108.Sun X, Frierson HF, Chen C, Li C, Ran Q, Otto KB, Cantarel BL, Vessella RL, Gao AC, Petros J, Miura Y, Simons JW, Dong JT. Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer. Nat Genet. 2005;37:407–12. doi: 10.1038/ng1528. [DOI] [PubMed] [Google Scholar]
109.Alipov G, Nakayama T, Ito M, Kawai K, Naito S, Nakashima M, Niino D, Sekine I. Overexpression of Ets-1 proto-oncogene in latent and clinical prostatic carcinomas. Histopathology. 2005;46:202–8. doi: 10.1111/j.1365-2559.2005.02059.x. [DOI] [PubMed] [Google Scholar]
110.Thelen P, Jarry H, Ringert RH, Wuttke W. Silibinin down-regulates prostate epithelium-derived Ets transcription factor in LNCaP prostate cancer cells. Planta Med. 2004;70:397–400. doi: 10.1055/s-2004-818965. [DOI] [PubMed] [Google Scholar]
111.Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644–8. doi: 10.1126/science.1117679. [DOI] [PubMed] [Google Scholar]
112.Isaacs JT. The biology of hormone refractory prostate cancer. Why does it develop. Urol Clin North Am. 1999;26:263–73. doi: 10.1016/s0094-0143(05)70066-5. [DOI] [PubMed] [Google Scholar]
113.Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature. 2004;432:332–7. doi: 10.1038/nature03096. [DOI] [PMC free article] [PubMed] [Google Scholar]
114.Micke P, Ostman A. Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy. Lung Cancer. 2004;45(Suppl 2):S163–75. doi: 10.1016/j.lungcan.2004.07.977. [DOI] [PubMed] [Google Scholar]
115.Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999;59:5002–11. doi: 10.1186/bcr138. [DOI] [PMC free article] [PubMed] [Google Scholar]
116.Hayward SW, Wang Y, Cao M, Hom YK, Zhang B, Grossfeld GD, Sudilovsky D, Cunha GR. Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Res. 2001;61:8135–42. [PubMed] [Google Scholar]
117.Begley L, Monteleon C, Shah RB, Macdonald JW, Macoska JA. CXCL12 overexpression and secretion by aging fibroblasts enhance human prostate epithelial proliferation in vitro. Aging Cell. 2005;4:291–8. doi: 10.1111/j.1474-9726.2005.00173.x. [DOI] [PubMed] [Google Scholar]
118.Rothhammer T, Hahne JC, Florin A, Poser I, Soncin F, Wernert N, Bosserhoff AK. The Ets-1 transcription factor is involved in the development and invasion of malignant melanoma. Cell Mol Life Sci. 2004;61:118–28. doi: 10.1007/s00018-003-3337-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
119.Hahne JC, Okuducu AF, Kaminski A, Florin A, Soncin F, Wernert N. Ets-1 expression promotes epithelial cell transformation by inducing migration, invasion and anchorage-independent growth. Oncogene. 2005;24:5384–8. doi: 10.1038/sj.onc.1208761. [DOI] [PubMed] [Google Scholar]
120.Wernert N, Okuducu AF, Pepper MS. Ets 1 is expressed in capillary blood vessels but not in lymphatics. J Pathol. 2003;200:561–7. doi: 10.1002/path.1380. [DOI] [PubMed] [Google Scholar]
121.Hill R, Song Y, Cardiff RD, Van Dyke T. Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell. 2005;123:1001–11. doi: 10.1016/j.cell.2005.09.030. [DOI] [PubMed] [Google Scholar]
122.Koeneman KS, Yeung F, Chung LW. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate. 1999;39:246–1. doi: 10.1002/(sici)1097-0045(19990601)39:4<246::aid-pros5>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
123.Chung LW, Baseman A, Assikis V, Zhau HE. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol. 2005;173:10–20. doi: 10.1097/01.ju.0000141582.15218.10. [DOI] [PubMed] [Google Scholar]
124.Koutsilieris M, van Ta R, Diblalexi D, Pitulis N, Sotiriou E, Lembessis P, Bogdanos J, Milathianakis C, Sourla A. Bone metastasis microenvironment participates in the development of androgen ablation refractoriness and chemotherapy resistance of prostate cancer cells residing in the skeleton: clinical implications. In: Meadows GG, editor. Integration/interaction of oncogenic growth. Springer; 2005. pp. 335–44. editor. . Dordrecht: [Google Scholar]
125.Djakiew D. Dysregulated expression of growth factors and their receptors in the development of prostate cancer. Prostate. 2000;42:150–60. doi: 10.1002/(sici)1097-0045(20000201)42:2<150::aid-pros10>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
126.van der Poel HG. Smart drugs in prostate cancer. Eur Urol. 2004;45:1–17. doi: 10.1016/j.eururo.2003.08.011. [DOI] [PubMed] [Google Scholar]
127.Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP, Guenther MG, Kumar RM, Murray HL, Jenner RG, Gifford DK, Melton DA, Jaenisch R, Young RA. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell. 2005;122:947–56. doi: 10.1016/j.cell.2005.08.020. [DOI] [PMC free article] [PubMed] [Google Scholar]
128.Chew JL, Loh YH, Zhang W, Chen X, Tam WL, Yeap LS, Li P, Ang YS, Lim B, Robson P, Ng HH. Reciprocal transcriptional regulation of Pou5f1 and Sox2 via the Oct4/Sox2 complex in embryonic stem cells. Mol Cell Biol. 2005;25:6031–46. doi: 10.1128/MCB.25.14.6031-6046.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
129.Miller SJ, Lavker RM, Sun TT. Interpreting epithelial cancer biology in the context of stem cells: tumor properties and therapeutic implications. Biochim Biophys Acta. 2005;1756:25–52. doi: 10.1016/j.bbcan.2005.07.003. [DOI] [PubMed] [Google Scholar]
130.Beachy PA, Karhadkar SS, Berman DM. Tissue repair and stem cell renewal in carcinogenesis. Nature. 2004;432:324–31. doi: 10.1038/nature03100. [DOI] [PubMed] [Google Scholar]
131.Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005;434:843–50. doi: 10.1038/nature03319. [DOI] [PubMed] [Google Scholar]
132.Karhadkar SS, Bova GS, Abdallah N, Dhara S, Gardner D, Maitra A, Isaacs JT, Berman DM, Beachy PA. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature. 2004;431:707–12. doi: 10.1038/nature02962. [DOI] [PubMed] [Google Scholar]
133.Fan L, Pepicelli CV, Dibble CC, Catbagan W, Zarycki JL, Laciak R, Gipp J, Shaw A, Lamm ML, Munoz A, Lipinski R, Thrasher JB, Bushman W. Hedgehog signaling promotes prostate xenograft tumor growth. Endocrinology. 2004;145:3961–70. doi: 10.1210/en.2004-0079. [DOI] [PubMed] [Google Scholar]
134.Sanchez P, Hernandez AM, Stecca B, Kahler AJ, de Gueme AM, Barrett A, Beyna M, Datta MW, Datta S, Altaba A. Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOGGLI1 signaling. Proc Natl Acad Sci USA. 2004;101:12561–6. doi: 10.1073/pnas.0404956101. [DOI] [PMC free article] [PubMed] [Google Scholar]
135.Sheng T, Li C, Zhang X, Chi S, He N, Chen K, McCormick F, Gatalica Z, Xie J. Activation of the hedgehog pathway in advanced prostate cancer. Mol Cancer. 2004;3:29. doi: 10.1186/1476-4598-3-29. [DOI] [PMC free article] [PubMed] [Google Scholar]
136.Podlasek CA, Barnett DH, Clemens JQ, Bak PM, Bushman W. Prostate development requires Sonic hedgehog expressed by the urogenital sinus epithelium. Dev Biol. 1999;209:28–39. doi: 10.1006/dbio.1999.9229. [DOI] [PubMed] [Google Scholar]
137.Barnett DH, Huang HY, Wu XR, Laciak R, Shapiro E, Bushman W. The human prostate expresses sonic hedgehog during fetal development. J Urol. 2002;168:2206–10. doi: 10.1016/S0022-5347(05)64356-X. [DOI] [PubMed] [Google Scholar]
138.Freestone SH, Marker P, Grace OC, Tomlinson DC, Cunha GR, Harnden P, Thomson AA. Sonic hedgehog regulates prostatic growth and epithelial differentiation. Dev Biol. 2003;264:352–62. doi: 10.1016/j.ydbio.2003.08.018. [DOI] [PubMed] [Google Scholar]
139.Sanchez P, Clement V, Altaba A. Therapeutic targeting of the Hedgehog-GLI pathway in prostate cancer. Cancer Res. 2005;65:2990–2. doi: 10.1158/0008-5472.CAN-05-0439. [DOI] [PubMed] [Google Scholar]
140.Kuzmichev A, Margueron R, Vaquero A, Preissner TS, Scher M, Kirmizis A, Ouyang X, Brockdorff N, Abate-Shen C, Farnham P, Reinberg D. Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc Natl Acad Sci USA. 2005;102:1859–64. doi: 10.1073/pnas.0409875102. [DOI] [PMC free article] [PubMed] [Google Scholar]
141.Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature. 2003;423:255–60. doi: 10.1038/nature01572. [DOI] [PubMed] [Google Scholar]
142.Dimri GP, Martinez JL, Jacobs JJ, Keblusek P, Itahana K, Van Lohuizen M, Campisi J, Wazer DE, Band V. The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. Cancer Res. 2002;62:4736–45. [PubMed] [Google Scholar]
143.Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest. 2005;115:1503–21. doi: 10.1172/JCI23412. [DOI] [PMC free article] [PubMed] [Google Scholar]
144.Hudson DL. Epithelial stem cells in human prostate growth and disease. Prostate Cancer Prostatic Dis. 2004;7:188–94. doi: 10.1038/sj.pcan.4500745. [DOI] [PubMed] [Google Scholar]
145.Peehl DM. Primary cell cultures as models of prostate cancer development. Endocr Relat Cancer. 2005;12:19–47. doi: 10.1677/erc.1.00795. [DOI] [PubMed] [Google Scholar]
146.Maitland NJ, Collins A. A tumour stem cell hypothesis for the origins of prostate cancer. BJU Int. 2005;96:1219–23. doi: 10.1111/j.1464-410X.2005.05744.x. [DOI] [PubMed] [Google Scholar]
147.Burger PE, Xiong X, Coetzee S, Salm SN, Moscatelli D, Goto K, Wilson EL. Sca-1 expression identifies stem cells in the proximal region of prostatic ducts with high capacity to reconstitute prostatic tissue. Proc Natl Acad Sci USA. 2005;102:7180–5. doi: 10.1073/pnas.0502761102. [DOI] [PMC free article] [PubMed] [Google Scholar]
148.Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci. 2004;117:3539–45. doi: 10.1242/jcs.01222. [DOI] [PubMed] [Google Scholar]
149.Xin L, Lawson DA, Witte ON. The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. Proc Natl Acad Sci USA. 2005;102:6942–7. doi: 10.1073/pnas.0502320102. [DOI] [PMC free article] [PubMed] [Google Scholar]
150.Kurita T, Medina RT, Mills AA, Cunha GR. Role of p63 and basal cells in the prostate. Development. 2004;131:4955–64. doi: 10.1242/dev.01384. [DOI] [PubMed] [Google Scholar]
151.Signoretti S, Pires MM, Lindauer M, Horner JW, Grisanzio C, Dhar S, Majumder P, McKeon F, Kantoff PW, Sellers WR, Loda M. p63 regulates commitment to the prostate cell lineage. Proc Natl Acad Sci USA. 2005;102:11355–60. doi: 10.1073/pnas.0500165102. [DOI] [PMC free article] [PubMed] [Google Scholar]
152.Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, Wahl M, Nisitani S, Yamashiro J, Le Beau MM, Loda M, Witte ON. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA. 1998;95:1735–40. doi: 10.1073/pnas.95.4.1735. [DOI] [PMC free article] [PubMed] [Google Scholar]
153.Tran CP, Lin C, Yamashiro J, Reiter RE. Prostate stem cell antigen is a marker of late intermediate prostate epithelial cells. Mol Cancer Res. 2002;1:113–21. [PubMed] [Google Scholar]
154.Lam JS, Yamashiro J, Shintaku IP, Vessella RL, Jenkins RB, Horvath S, Said JW, Reiter RE. Prostate stem cell antigen is overexpressed in prostate cancer metastases. Clin Cancer Res. 2005;11:2591–6. doi: 10.1158/1078-0432.CCR-04-1842. [DOI] [PubMed] [Google Scholar]
155.Van Leenders GJ, Gage WR, Hicks JL, Van Balken B, Aalders TW, Schalken JA, de Marzo AM. Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy. Am J Pathol. 2003;162:1529–37. doi: 10.1016/S0002-9440(10)64286-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
156.Epstein JI. Diagnosis and reporting of limited adenocarcinoma of the prostate on needle biopsy. Mod Pathol. 2004;17:307–15. doi: 10.1038/modpathol.3800050. [DOI] [PubMed] [Google Scholar]
157.Enokida H, Shiina H, Igawa M, Ogishima T, Kawakami T, Bassett WW, Anast JW, Li LC, Urakami S, Terashima M, Verma M, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R. CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer. Cancer Res. 2004;64:5956–62. doi: 10.1158/0008-5472.CAN-04-0081. [DOI] [PubMed] [Google Scholar]
158.Lou W, Krill D, Dhir R, Becich MJ, Dong JT, Frierson HF, Jr, Isaacs WB, Isaacs JT, Gao AC. Methylation of the CD44 metastasis suppressor gene in human prostate cancer. Cancer Res. 1999;59:2329–31. [PubMed] [Google Scholar]
159.Verkaik NS, Van Steenbrugge GJ, Van Weerden WM, Bussemakers MJ, van der Kwast TH. Silencing of CD44 expression in prostate cancer by hypermethylation of the CD44 promoter region. Lab Invest. 2000;80:1291–8. doi: 10.1038/labinvest.3780137. [DOI] [PubMed] [Google Scholar]
160.Kito H, Suzuki H, Ichikawa T, Sekita N, Kamiya N, Akakura K, Igarashi T, Nakayama T, Watanabe M, Harigaya K, Ito H. Hypermethylation of the CD44 gene is associated with progression and metastasis of human prostate cancer. Prostate. 2001;49:110–5. doi: 10.1002/pros.1124. [DOI] [PubMed] [Google Scholar]
161.Reiter RE, Sato I, Thomas G, Qian J, Gu Z, Watabe T, Loda M, Jenkins RB. Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer. Genes Chromosomes Cancer. 2000;27:95–103. doi: 10.1002/(sici)1098-2264(200001)27:1<95::aid-gcc12>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
162.Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005;65:10946–51. doi: 10.1158/0008-5472.CAN-05-2018. [DOI] [PubMed] [Google Scholar]
163.Ohlsson R, Kanduri C, Whitehead J, Pfeifer S, Lobanenkov V, Feinberg AP. Epigenetic variability and the evolution of human cancer. Adv Cancer Res. 2003;88:145–68. doi: 10.1016/s0065-230x(03)88306-9. [DOI] [PubMed] [Google Scholar]
164.Kallakury BV, Sheehan CE, Winn-Deen E, Oliver J, Fisher HA, Kaufman RP, Jr, Ross JS. Decreased expression of catenins (alpha and beta), p120 CTN, and E-cadherin cell adhesion proteins and E-cadherin gene promoter methylation in prostatic adenocarcinomas. Cancer. 2001;92:2786–95. doi: 10.1002/1097-0142(20011201)92:11<2786::aid-cncr10128>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
165.Lai JS, Brown LG, True LD, Hawley SJ, Etzioni RB, Higano CS, Ho SM, Vessella RL, Corey E. Metastases of prostate cancer express estrogen receptor-β. Urology. 2004;64:814–20. doi: 10.1016/j.urology.2004.05.036. [DOI] [PubMed] [Google Scholar]
166.Zhu X, Leav I, Leung YK, Wu M, Liu Q, Gao Y, McNeal JE, Ho SM. Dynamic regulation of estrogen receptor-β expression by DNA methylation during prostate cancer development and metastasis. Am J Pathol. 2004;164:2003–12. doi: 10.1016/s0002-9440(10)63760-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
167.Yang G, Truong LD, Timme TL, Ren C, Wheeler TM, Park SH, Nasu Y, Bangma CH, Kattan MW, Scardino PT, Thompson TC. Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res. 1998;4:1873–80. [PubMed] [Google Scholar]
168.Cui J, Rohr LR, Swanson G, Speights VO, Maxwell T, Brothman AR. Hypermethylation of the caveolin-1 gene promoter in prostate cancer. Prostate. 2001;46:249–56. doi: 10.1002/1097-0045(20010215)46:3<249::aid-pros1030>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
169.Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM. Delineation of prognostic biomarkers in prostate cancer. Nature. 2001;412:822–6. doi: 10.1038/35090585. [DOI] [PubMed] [Google Scholar]
170.Magee JA, Araki T, Patil S, Ehrig T, True L, Humphrey PA, Catalona WJ, Watson MA, Milbrandt J. Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res. 2001;61:5692–6. [PubMed] [Google Scholar]
171.Stephan C, Yousef GM, Scorilas A, Jung K, Jung M, Kristiansen G, Hauptmann S, Kishi T, Nakamura T, Loening SA, Diamandis EP. Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer. J Urol. 2004;171:187–91. doi: 10.1097/01.ju.0000101622.74236.94. [DOI] [PubMed] [Google Scholar]
172.Srikantan V, Valladares M, Rhim JS, Moul JW, Srivastava S. HEPSIN inhibits cell growth/invasion in prostate cancer cells. Cancer Res. 2002;62:6812–6. [PubMed] [Google Scholar]
173.Klezovitch O, Chevillet J, Mirosevich J, Roberts RL, Matusik RJ, Vasioukhin V. Hepsin promotes prostate cancer progression and metastasis. Cancer Cell. 2004;6:185–95. doi: 10.1016/j.ccr.2004.07.008. [DOI] [PubMed] [Google Scholar]
174.Wong AK, Shanahan F, Chen Y, Lian L, Ha P, Hendricks K, Ghaffari S, Iliev D, Penn B, Woodland AM, Smith R, Salada G, Carillo A, Laity K, Gupte J, Swedlund B, Tavtigian SV, van Gan DH, Lees E. BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines. Cancer Res. 2000;60:6171–7. [PubMed] [Google Scholar]
175.Valdman A, Nordenskjold A, Fang X, Naito A, Al Shukri S, Larsson C, Ekman P, Li C. Mutation analysis of the BRG1 gene in prostate cancer clinical samples. Int J Oncol. 2003;22:1003–7. [PubMed] [Google Scholar]
176.Filippova GN, Qi CF, Ulmer JE, Moore JM, Ward MD, Hu YJ, Loukinov DI, Pugacheva EM, Klenova EM, Grundy PE, Feinberg AP, Cleton-Jansen AM, Moerland EW, Cornelisse CJ, Suzuki H, Komiya A, Lindblom A, Dorion-Bonnet F, Neiman PE, Morse HC, III, Collins SJ, Lobanenkov VV. Tumor-associated zinc finger mutations in the CTCF transcription factor selectively alter its DNA-binding specificity. Cancer Res. 2002;62:48–52. [PubMed] [Google Scholar]
177.Hong JA, Kang Y, Abdullaev Z, Flanagan PT, Pack SD, Fischette MR, Adnani MT, Loukinov DI, Vatolin S, Risinger JI, Custer M, Chen GA, Zhao M, Nguyen DM, Barrett JC, Lobanenkov VV, Schrump DS. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Cancer Res. 2005;65:7763–74. doi: 10.1158/0008-5472.CAN-05-0823. [DOI] [PubMed] [Google Scholar]
178.Tamimi Y, van der Poel HG, de Nyn MM, Umbas R, Karthaus HF, de Bruyne FM, Schalken JA. Increased expression of high mobility group protein I(Y) in high grade prostatic cancer determined by in situ hybridization. Cancer Res. 1993;53:5512–6. [PubMed] [Google Scholar]
179.Katoh M. Expression of human SOX7 in normal tissues and tumors. Int J Mol Med. 2002;9:363–8. [PubMed] [Google Scholar]

[b1] 1.Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970–2002. JAMA. 2005;294:1255–9. doi: 10.1001/jama.294.10.1255. [DOI] [PubMed] [Google Scholar]

[b2] 2.Schalken JA, Bergh A, Bono A, Foster C, Gospadarowicz M, Isaacs WB, Rubin M, Schroder F, Tribukait B, Tsukamotot T, Wiklund P. Molecular prostate cancer pathology: current issues and achievements. Scand J Urol Nephrol Suppl. 2005:82–93. doi: 10.1080/03008880510030950. [DOI] [PubMed] [Google Scholar]

[b3] 3.Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J, Morrison H, Sonawane B, Shifflett T, Waters DJ, Timms B. Human prostate cancer risk factors. Cancer. 2004;101:2371–490. doi: 10.1002/cncr.20408. [DOI] [PubMed] [Google Scholar]

[b4] 4.Bratt O. Hereditary prostate cancer: clinical aspects. J Urol. 2002;168:906–13. doi: 10.1016/S0022-5347(05)64541-7. [DOI] [PubMed] [Google Scholar]

[b5] 5.Simard J, Dumont M, Soucy P, Labrie F. Perspective: prostate cancer susceptibility genes. Endocrinology. 2002;143:2029–40. doi: 10.1210/endo.143.6.8890. [DOI] [PubMed] [Google Scholar]

[b6] 6.Silverman RH. Implications for RNase L in prostate cancer biology. Biochemistry. 2003;42:1805–12. doi: 10.1021/bi027147i. [DOI] [PubMed] [Google Scholar]

[b7] 7.Nelson WG, de Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med. 2003;349:366–81. doi: 10.1056/NEJMra021562. [DOI] [PubMed] [Google Scholar]

[b8] 8.Andriole G, Bostwick D, Civantos F, Epstein J, Lucia MS, McConnell J, Roehrborn CG. The effects of 5α-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge. J Urol. 2005;174:2098–104. doi: 10.1097/01.ju.0000181216.71605.38. [DOI] [PubMed] [Google Scholar]

[b9] 9.Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001;1:34–45. doi: 10.1038/35094009. [DOI] [PubMed] [Google Scholar]

[b10] 10.Jarrard DF, Kinoshita H, Shi Y, Sandefur C, Hoff D, Meisner LF, Chang C, Herman JG, Isaacs WB, Nassif N. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer Res. 1998;58:5310–4. [PubMed] [Google Scholar]

[b11] 11.Dong JT. Chromosomal deletions and tumor suppressor genes in prostate cancer. Cancer Metastasis Rev. 2001;20:173–93. doi: 10.1023/a:1015575125780. [DOI] [PubMed] [Google Scholar]

[b12] 12.Schulz WA, Burchardt M, Cronauer MV. Molecular biology of prostate cancer. Mol Hum Reprod. 2003;9:437–48. doi: 10.1093/molehr/gag064. [DOI] [PubMed] [Google Scholar]

[b13] 13.Porkka KP, Visakorpi T. Molecular mechanisms of prostate cancer. Eur Urol. 2004;45:683–91. doi: 10.1016/j.eururo.2004.01.012. [DOI] [PubMed] [Google Scholar]

[b14] 14.Kindich R, Florl AR, Kamradt J, Lehmann J, Müller M, Wullich B, Schulz WA. Relationship of NKX3.1 and MYC gene copy number ratio and DNA hypomethylation to prostate carcinoma stage. Eur Urol. 2006;49:169–75. doi: 10.1016/j.eururo.2005.09.012. [DOI] [PubMed] [Google Scholar]

[b15] 15.Nakayama M, Gonzalgo ML, Yegnasubramanian S, Lin X, de Marzo AM, Nelson WG. GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J Cell Biochem. 2004;91:540–52. doi: 10.1002/jcb.10740. [DOI] [PubMed] [Google Scholar]

[b16] 16.Holliday R. Epigenetics: an overview. Dev Genet. 1994;15:453–7. doi: 10.1002/dvg.1020150602. [DOI] [PubMed] [Google Scholar]

[b17] 17.Slack JM. Conrad Hal Waddington: the last Renaissance biologist. Nat Rev Genet. 2002;3:889–95. doi: 10.1038/nrg933. [DOI] [PubMed] [Google Scholar]

[b18] 18.de Ininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96:3343–56. [PubMed] [Google Scholar]

[b19] 19.Jarrard DF, Bussemakers MJ, Bova GS, Isaacs WB. Regional loss of imprinting of the insulin-like growth factor II gene occurs in human prostate tissues. Clin Cancer Res. 1995;1:1471–8. [PubMed] [Google Scholar]

[b20] 20.Florl AR, Steinhoff C, Muller M, Seifert HH, Hader C, Engers R, Ackermann R, Schulz WA. Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. Br J Cancer. 2004;91:985–994. doi: 10.1038/sj.bjc.6602030. [DOI] [PMC free article] [PubMed] [Google Scholar]

[b21] 21.Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, Bova GS, de Marzo AM, Isaacs WB, Nelson WG. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res. 2004;64:1975–86. doi: 10.1158/0008-5472.can-03-3972. [DOI] [PubMed] [Google Scholar]

[b22] 22.Cookson MS, Reuter VE, Linkov I, Fair WR. Glutathione S-transferase PI (GST-pi) class expression by immunohistochemistry in benign and malignant prostate tissue. J Urol. 1997;157:673–6. [PubMed] [Google Scholar]

[b23] 23.Nakayama T, Watanabe M, Yamanaka M, Hirokawa Y, Suzuki H, Ito H, Yatani R, Shiraishi T. The role of epigenetic modifications in retinoic acid receptor β2 gene expression in human prostate cancers. Lab Invest. 2001;81:1049–57. doi: 10.1038/labinvest.3780316. [DOI] [PubMed] [Google Scholar]

[b24] 24.Dammann R, Schagdarsurengin U, Seidel C, Strunnikova M, Rastetter M, Baier K, Pfeifer GP. The tumor suppressor RASSF1A in human carcinogenesis: an update. Histol Histopathol. 2005;20:645–63. doi: 10.14670/HH-20.645. [DOI] [PubMed] [Google Scholar]

[b25] 25.Tsuchiya T, Tamura G, Sato K, Endoh Y, Sakata K, Jin Z, Motoyama T, Usuba O, Kimura W, Nishizuka S, Wilson KT, James SP, Yin J, Fleisher AS, Zou T, Silverberg SG, Kong D, Meltzer SJ. Distinct methylation patterns of two APC gene promoters in normal and cancerous gastric epithelia. Oncogene. 2000;19:3642–6. doi: 10.1038/sj.onc.1203704. [DOI] [PubMed] [Google Scholar]

[b26] 26.Santourlidis S, Florl A, Ackermann R, Wirtz HC, Schulz WA. High frequency of alterations in DNA methylation in adenocarcinoma of the prostate. Prostate. 1999;39:166–74. doi: 10.1002/(sici)1097-0045(19990515)39:3<166::aid-pros4>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]

[b27] 27.Tokizane T, Shiina H, Igawa M, Enokida H, Urakami S, Kawakami T, Ogishima T, Okino ST, Li LC, Tanaka Y, Nonomura N, Okuyama A, Dahiya R. Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer. Clin Cancer Res. 2005;11:5793–801. doi: 10.1158/1078-0432.CCR-04-2545. [DOI] [PubMed] [Google Scholar]

[b28] 28.Ogishima T, Shiina H, Breault JE, Tabatabai L, Bassett WW, Enokida H, Li LC, Kawakami T, Urakami S, Ribeiro-Filho LA, Terashima M, Fujime M, Igawa M, Dahiya R. Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer. Clin Cancer Res. 2005;11:1028–36. [PubMed] [Google Scholar]

[b29] 29.Laner T, Schulz WA, Engers R, Muller M, Florl AR. Hypomethylation of the XIST gene promoter in prostate cancer. Oncol Res. 2005;15:257–64. doi: 10.3727/096504005776404607. [DOI] [PubMed] [Google Scholar]

[b30] 30.Hoffmann MJ, Schulz WA. Causes and consequences of DNA hypomethylation in human cancer. Biochem Cell Biol. 2005;83:296–321. doi: 10.1139/o05-036. [DOI] [PubMed] [Google Scholar]

[b31] 31.Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3:415–28. doi: 10.1038/nrg816. [DOI] [PubMed] [Google Scholar]

[b32] 32.Ballestar E, Esteller M. Methyl-CpG-binding proteins in cancer: blaming the DNA methylation messenger. Biochem Cell Biol. 2005;83:374–84. doi: 10.1139/o05-035. [DOI] [PubMed] [Google Scholar]

[b33] 33.Robertson KD. DNA methylation and human disease. Nat Rev Genet. 2005;6:597–610. doi: 10.1038/nrg1655. [DOI] [PubMed] [Google Scholar]

[b34] 34.Santoro R, de Lucia F. Many players, one goal: how chromatin states are inherited during cell division. Biochem Cell Biol. 2005;83:332–343. doi: 10.1139/o05-021. [DOI] [PubMed] [Google Scholar]

[b35] 35.Patra SK, Patra A, Zhao H, Carroll P, Dahiya R. Methyl-CpG-DNA binding proteins in human prostate cancer: expression of CXXC sequence containing MBD1 and repression of MBD2 and MeCP2. Biochem Biophys Res Commun. 2003;302:759–66. doi: 10.1016/s0006-291x(03)00253-5. [DOI] [PubMed] [Google Scholar]

[b36] 36.Freitag M, Selker EU. Controlling DNA methylation: many roads to one modification. Curr Opin Genet Dev. 2005;15:191–9. doi: 10.1016/j.gde.2005.02.003. [DOI] [PubMed] [Google Scholar]

[b37] 37.Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002;419:624–9. doi: 10.1038/nature01075. [DOI] [PubMed] [Google Scholar]

[b38] 38.Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J. 2003;22:5323–35. doi: 10.1093/emboj/cdg542. [DOI] [PMC free article] [PubMed] [Google Scholar]

[b39] 39.Tang X, Milyavsky M, Shats I, Erez N, Goldfinger N, Rotter V. Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene. 2004;23:5759–69. doi: 10.1038/sj.onc.1207706. [DOI] [PubMed] [Google Scholar]

[b40] 40.Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, Kurdistani SK. Global histone modification patterns predict risk of prostate cancer recurrence. Nature. 2005;435:1262–1266. doi: 10.1038/nature03672. [DOI] [PubMed] [Google Scholar]

[b41] 41.Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K, Iyer NG, Perez-Rosado A, Calvo E, Lopez JA, Cano A, Calasanz MJ, Colomer D, Piris MA, Ahn N, Imhof A, Caldas C, Jenuwein T, Esteller M. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet. 2005;37:391–400. doi: 10.1038/ng1531. [DOI] [PubMed] [Google Scholar]

[b42] 42.Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, Casero RA, Shi Y. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 2004;119:941–53. doi: 10.1016/j.cell.2004.12.012. [DOI] [PubMed] [Google Scholar]

[b43] 43.Metzger E, Wissmann M, Yin N, Muller JM, Schneider R, Peters AH, Gunther T, Buettner R, Schule R. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature. 2005;437:436–9. doi: 10.1038/nature04020. [DOI] [PubMed] [Google Scholar]

[b44] 44.Knossl M, Lower R, Lower J. Expression of the human endogenous retrovirus HTDV/ HERV-K is enhanced by cellular transcription factor YY1. J Virol. 1999;73:1254–61. doi: 10.1128/jvi.73.2.1254-1261.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]

[b45] 45.Seligson D, Horvath S, Huerta-Yepez S, Hanna S, Garban H, Roberts A, Shi T, Liu X, Chia D, Goodglick L, Bonavida B. Expression of transcription factor Yin Yang 1 in prostate cancer. Int J Oncol. 2005;27:131–41. [PubMed] [Google Scholar]

[b46] 46.Schulz WA, Elo JP, Florl AR, Pennanen S, Santourlidis S, Engers R, Buchardt M, Seifert HH, Visakorpi T. Genomewide DNA hypomethylation is associated with alterations on chromosome 8 in prostate carcinoma. Genes Chromosomes Cancer. 2002;35:58–65. doi: 10.1002/gcc.10092. [DOI] [PubMed] [Google Scholar]

[b47] 47.Klenova EM, Morse HC, III, Ohlsson R, Lobanenkov VV. The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer. Semin Cancer Biol. 2002;12:399–414. doi: 10.1016/s1044-579x(02)00060-3. [DOI] [PubMed] [Google Scholar]

[b48] 48.Leman ES, Madigan MC, Brunagel G, Takaha N, Coffey DS, Getzenberg RH. Nuclear matrix localization of high mobility group protein I(Y) in a transgenic mouse model for prostate cancer. J Cell Biochem. 2003;88:599–608. doi: 10.1002/jcb.10368. [DOI] [PubMed] [Google Scholar]

[b49] 49.Takaha N, Hawkins AL, Griffin CA, Isaacs WB, Coffey DS. High mobility group protein I(Y): a candidate architectural protein for chromosomal rearrangements in prostate cancer cells. Cancer Res. 2002;62:647–51. [PubMed] [Google Scholar]

[b50] 50.Hofer MD, Kuefer R, Varambally S, Li H, Ma J, Shapiro GI, Gschwend JE, Hautmann RE, Sanda MG, Giehl K, Menke A, Chinnaiyan AM, Rubin MA. The role of metastasis-associated protein 1 in prostate cancer progression. Cancer Res. 2004;64:825–9. doi: 10.1158/0008-5472.can-03-2755. [DOI] [PubMed] [Google Scholar]

[b51] 51.Li LC, Carroll PR, Dahiya R. Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst. 2005;97:103–15. doi: 10.1093/jnci/dji010. [DOI] [PubMed] [Google Scholar]

[b52] 52.Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol. 2005;45:495–528. doi: 10.1146/annurev.pharmtox.45.120403.095825. [DOI] [PubMed] [Google Scholar]

[b53] 53.Lyko F, Brown R. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst. 2005;97:1498–506. doi: 10.1093/jnci/dji311. [DOI] [PubMed] [Google Scholar]

[b54] 54.Cronauer MV, Schulz WA, Burchardt T, Anastasiadis AG, de La TA, Ackermann R, Burchardt M. The androgen receptor in hormonerefractory prostate cancer: relevance of different mechanisms of androgen receptor signaling (Review) Int J Oncol. 2003;23:1095–102. doi: 10.3892/ijo.23.4.1095. [DOI] [PubMed] [Google Scholar]

[b55] 55.Culig Z, Comuzzi B, Steiner H, Bartsch G, Hobisch A. Expression and function of androgen receptor coactivators in prostate cancer. J Steroid Biochem Mol Biol. 2004;92:265–71. doi: 10.1016/j.jsbmb.2004.10.003. [DOI] [PubMed] [Google Scholar]

[b56] 56.Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev. 2004;25:276–308. doi: 10.1210/er.2002-0032. [DOI] [PubMed] [Google Scholar]

[b57] 57.Linja MJ, Visakorpi T. Alterations of androgen receptor in prostate cancer. J Steroid Biochem Mol Biol. 2004;92:255–64. doi: 10.1016/j.jsbmb.2004.10.012. [DOI] [PubMed] [Google Scholar]

[b58] 58.Yang Y, Hou H, Haller EM, Nicosia SV, Bai W. Suppression of FOXO1 activity by FHL2 through SIRT1-mediated deacetylation. EMBO J. 2005;24:1021–32. doi: 10.1038/sj.emboj.7600570. [DOI] [PMC free article] [PubMed] [Google Scholar]

[b59] 59.Khanim FL, Gommersall LM, Wood VH, Smith KL, Montalvo L, O'Neill LP, Xu Y, Peehl DM, Stewart PM, Turner BM, Campbell MJ. Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells. Oncogene. 2004;23:6712–25. doi: 10.1038/sj.onc.1207772. [DOI] [PubMed] [Google Scholar]

[b60] 60.Chua SS, Ma Z, Ngan E, Tsai SY. Cdc25B as a steroid receptor coactivator. Vitam Horm. 2004;68:231–56. doi: 10.1016/S0083-6729(04)68008-3. [DOI] [PubMed] [Google Scholar]

[b61] 61.Lim JT, Mansukhani M, Weinstein IB. Cyclindependent kinase 6 associates with the androgen receptor and enhances its transcriptional activity in prostate cancer cells. Proc Natl Acad Sci USA. 2005;102:5156–61. doi: 10.1073/pnas.0501203102. [DOI] [PMC free article] [PubMed] [Google Scholar]

[b62] 62.Petre CE, Wetherill YB, Danielsen M, Knudsen KE. Cyclin D1: mechanism and consequence of androgen receptor co-repressor activity. J Biol Chem. 2002;277:2207–15. doi: 10.1074/jbc.M106399200. [DOI] [PubMed] [Google Scholar]

[b63] 63.Zwijsen RM, Wientjens E, Klompmaker R, Van de Ran SJ, Bernards R, Michalides RJ. CDK-independent activation of estrogen receptor by cyclin D1. Cell. 1997;88:405–15. doi: 10.1016/s0092-8674(00)81879-6. [DOI] [PubMed] [Google Scholar]

[b64] 64.Knudsen KE, Arden KC, Cavenee WK. Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells. J Biol Chem. 1998;273:20213–22. doi: 10.1074/jbc.273.32.20213. [DOI] [PubMed] [Google Scholar]

[b65] 65.Han EK, Lim JT, Arber N, Rubin MA, Xing WQ, Weinstein IB. Cyclin D1 expression in human prostate carcinoma cell lines and primary tumors. Prostate. 1998;35:95–101. doi: 10.1002/(sici)1097-0045(19980501)35:2<95::aid-pros2>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]

[b66] 66.Shiraishi T, Watanabe M, Muneyuki T, Nakayama T, Morita J, Ito H, Kotake T, Yatani R. A clinicopathological study of p53, p21 (WAF1/CIP1) and cyclin D1 expression in human prostate cancers. Urol Int. 1998;61:90–4. doi: 10.1159/000030295. [DOI] [PubMed] [Google Scholar]

[b67] 67.Bernard D, Pourtier-Manzanedo A, Gil J, Beach DH. Myc confers androgen-independent prostate cancer cell growth. J Clin Invest. 2003;112:1724–31. doi: 10.1172/JCI19035. [DOI] [PMC free article] [PubMed] [Google Scholar]

[b68] 68.Zhang XY, de Salle LM, Patel JH, Capobianco AJ, Yu D, Thomas-Tikhonenko A, McMahon SB. Metastasis-associated protein 1 (MTA1) is an essential downstream effector of the c-MYC oncoprotein. Proc Natl Acad Sci USA. 2005;102:13968–73. doi: 10.1073/pnas.0502330102. [DOI] [PMC free article] [PubMed] [Google Scholar]

[b69] 69.Savinainen KJ, Linja MJ, Saramaki OR, Tammela TL, Chang GT, Brinkmann AO, Visakorpi T. Expression and copy number analysis of TRPS1, EIF3S3 and MYC genes in breast and prostate cancer. Br J Cancer. 2004;90:1041–6. doi: 10.1038/sj.bjc.6601648. [DOI] [PMC free article] [PubMed] [Google Scholar]

[b70] 70.Verras M, Sun Z. Roles and regulation of Wnt signaling and β-catenin in prostate cancer. Cancer Lett. 2005 doi: 10.1016/j.canlet.2005.06.004. [DOI] [PubMed] [Google Scholar]

[b71] 71.Li LC, Okino ST, Dahiya R. DNA methylation in prostate cancer. Biochim Biophys Acta. 2004;1704:87–102. doi: 10.1016/j.bbcan.2004.06.001. [DOI] [PubMed] [Google Scholar]

[b72] 72.Schulz WA, Seifert HH. DNA methylation in urological cancers. In: Szyf M, editor. DNA methylation and cancer therapy. Landes Biosciences; 2004. pp. 42–58. Georgetown: [Google Scholar]

[b73] 73.Yang F, Li X, Sharma M, Sasaki CY, Longo DL, Lim B, Sun Z. Linking β-catenin to androgen-signaling pathway. J Biol Chem. 2002;277:11336–44. doi: 10.1074/jbc.M111962200. [DOI] [PubMed] [Google Scholar]

[b74] 74.Chesire DR, Isaacs WB. Ligand-dependent inhibition of β-catenin/TCF signaling by androgen receptor. Oncogene. 2002;21:8453–69. doi: 10.1038/sj.onc.1206049. [DOI] [PubMed] [Google Scholar]

[b75] 75.Cronauer MV, Schulz WA, Ackermann R, Burchardt M. Effects of WNT/β-catenin pathway activation on signaling through T-cell factor and androgen receptor in prostate cancer cell lines. Int J Oncol. 2005;26:1033–40. doi: 10.3892/ijo.26.4.1033. [DOI] [PubMed] [Google Scholar]

[b76] 76.Masiello D, Chen SY, Xu Y, Verhoeven MC, Choi E, Hollenberg AN, Balk SP. Recruitment of β-catenin by wild-type or mutant androgen receptors correlates with ligand-stimulated growth of prostate cancer cells. Mol Endocrinol. 2004;18:2388–401. doi: 10.1210/me.2003-0436. [DOI] [PubMed] [Google Scholar]

[b77] 77.Amir AL, Barua M, McKnight NC, Cheng S, Yuan X, Balk SP. A direct β-catenin-independent interaction between androgen receptor and T cell factor 4. J Biol Chem. 2003;278:30828–34. doi: 10.1074/jbc.M301208200. [DOI] [PubMed] [Google Scholar]

[b78] 78.Jung C, Kim RS, Lee SJ, Wang C, Jeng MH. HOXB13 homeodomain protein suppresses the growth of prostate cancer cells by the negative regulation of T-cell factor 4. Cancer Res. 2004;64:3046–51. doi: 10.1158/0008-5472.can-03-2614. [DOI] [PubMed] [Google Scholar]

[b79] 79.Jung C, Kim RS, Zhang HJ, Lee SJ, Jeng MH. HOXB13 induces growth suppression of prostate cancer cells as a repressor of hormone-activated androgen receptor signaling. Cancer Res. 2004;64:9185–92. doi: 10.1158/0008-5472.CAN-04-1330. [DOI] [PubMed] [Google Scholar]

[b80] 80.Halkidou K, Gnanapragasam VJ, Mehta PB, Logan IR, Brady ME, Cook S, Leung HY, Neal DE, Robson CN. Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene. 2003;22:2466–77. doi: 10.1038/sj.onc.1206342. [DOI] [PubMed] [Google Scholar]

[b81] 81.Kim JH, Kim B, Cai L, Choi HJ, Ohgi KA, Tran C, Chen C, Chung CH, Huber O, Rose DW, Sawyers CL, Rosenfeld MG, Baek SH. Transcriptional regulation of a metastasis suppressor gene by Tip60 and β-catenin complexes. Nature. 2005;434:921–6. doi: 10.1038/nature03452. [DOI] [PubMed] [Google Scholar]

[b82] 82.Dong JT, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT, Barrett JC. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science. 1995;268:884–6. doi: 10.1126/science.7754374. [DOI] [PubMed] [Google Scholar]

[b83] 83.Marreiros A, Dudgeon K, Dao V, Grimm MO, Czolij R, Crossley M, Jackson P. KAI1 promoter activity is dependent on p53, junB and AP2: evidence for a possible mechanism underlying loss of KAI1 expression in cancer cells. Oncogene. 2005;24:637–49. doi: 10.1038/sj.onc.1208216. [DOI] [PubMed] [Google Scholar]

[b84] 84.Shen MM, Abate-Shen C. Roles of the Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis. Dev Dyn. 2003;228:767–78. doi: 10.1002/dvdy.10397. [DOI] [PubMed] [Google Scholar]

[b85] 85.Kim MJ, Cardiff RD, de Sai N, Banach-Petrosky WA, Parsons R, Shen MM, Abate-Shen C. Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci USA. 2002;99:2884–9. doi: 10.1073/pnas.042688999. [DOI] [PMC free article] [PubMed] [Google Scholar]

[b86] 86.Abate-Shen C, Banach-Petrosky WA, Sun X, Economides KD, de Sai N, Gregg JP, Borowsky AD, Cardiff RD, Shen MM. Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. Cancer Res. 2003;63:3886–90. [PubMed] [Google Scholar]

[b87] 87.Gao H, Ouyang X, Banach-Petrosky W, Borowsky AD, Lin Y, Kim M, Lee H, Shih WJ, Cardiff RD, Shen MM, Abate-Shen C. A critical role for p27kip1 gene dosage in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci USA. 2004;101:17204–9. doi: 10.1073/pnas.0407693101. [DOI] [PMC free article] [PubMed] [Google Scholar]

[b88] 88.Bhatia-Gaur R, Donjacour AA, Sciavolino PJ, Kim M, de Sai N, Young P, Norton CR, Gridley T, Cardiff RD, Cunha GR, Abate-Shen C, Shen MM. Roles for Nkx3.1 in prostate development and cancer. Genes Dev. 1999;13:966–77. doi: 10.1101/gad.13.8.966. [DOI] [PMC free article] [PubMed] [Google Scholar]

[b89] 89.Asatiani E, Huang WX, Wang A, Rodriguez OE, Cavalli LR, Haddad BR, Gelmann EP. Deletion, methylation, and expression of the NKX3.1 suppressor gene in primary human prostate cancer. Cancer Res. 2005;65:1164–73. doi: 10.1158/0008-5472.CAN-04-2688. [DOI] [PubMed] [Google Scholar]

[b90] 90.Magee JA, Abdulkadir SA, Milbrandt J. Haploinsufficiency at the Nkx3.1 locus. A paradigm for stochastic, dosage-sensitive gene regulation during tumor initiation. Cancer Cell. 2003;3:273–283. doi: 10.1016/s1535-6108(03)00047-3. [DOI] [PubMed] [Google Scholar]

[b91] 91.Trotman LC, Niki M, Dotan ZA, Koutcher JA, Von Cristofano A, Xiao A, Khoo AS, Roy-Burman P, Greenberg NM, Van Dyke T, Cordon-Cardo C, Pandolfi PP. Pten dose dictates cancer progression in the prostate. PLoS Biol. 2003;1:E59. doi: 10.1371/journal.pbio.0000059. [DOI] [PMC free article] [PubMed] [Google Scholar]

[b92] 92.Tsihlias J, Kapusta LR, de Boer G, Morava-Protzner I, Zbieranowski I, Bhattacharya N, Catzavelos GC, Klotz LH, Slingerland JM. Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res. 1998;58:542–548. [PubMed] [Google Scholar]

[b93] 93.Yang RM, Naitoh J, Murphy M, Wang HJ, Phillipson J, de Kernion JB, Loda M, Reiter RE. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol. 1998;159:941–945. [PubMed] [Google Scholar]

[b94] 94.Cordon-Cardo C, Koff A, Drobnjak M, Capodieci P, Osman I, Millard SS, Gaudin PB, Fazzari M, Zhang ZF, Massague J, Scher HI. Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst. 1998;90:1284–1291. doi: 10.1093/jnci/90.17.1284. [DOI] [PubMed] [Google Scholar]

[b95] 95.Kibel AS, Christopher M, Faith DA, Bova GS, Goodfellow PJ, Isaacs WB. Methylation and mutational analysis of p27(kip1) in prostate carcinoma. Prostate. 2001;48:248–253. doi: 10.1002/pros.1104. [DOI] [PubMed] [Google Scholar]

[b96] 96.Zeltser L, de Splan C, Heintz N. Hoxb-13: a new Hox gene in a distant region of the HOXB cluster maintains colinearity. Development. 1996;122:2475–2484. doi: 10.1242/dev.122.8.2475. [DOI] [PubMed] [Google Scholar]

[b97] 97.Economides KD, Capecchi MR. Hoxb13 is required for normal differentiation and secretory function of the ventral prostate. Development. 2003;130:2061–2069. doi: 10.1242/dev.00432. [DOI] [PubMed] [Google Scholar]

[b98] 98.Dhanasekaran SM, Dash A, Yu J, Maine IP, Laxman B, Tomlins SA, Creighton CJ, Menon A, Rubin MA, Chinnaiyan AM. Molecular profiling of human prostate tissues: insights into gene expression patterns of prostate development during puberty. FASEB J. 2005;19:243–245. doi: 10.1096/fj.04-2415fje. [DOI] [PubMed] [Google Scholar]

[b99] 99.Jung C, Kim RS, Zhang H, Lee SJ, Sheng H, Loehrer PJ, Gardner TA, Jeng MH, Kao C. HOXB13 is downregulated in colorectal cancer to confer TCF4-mediated transactivation. Br J Cancer. 2005;92:2233–2239. doi: 10.1038/sj.bjc.6602631. [DOI] [PMC free article] [PubMed] [Google Scholar]

[b100] 100.Edwards S, Campbell C, Flohr P, Shpley J, Giddings I, Te-Poele R, Dodson A, Foster C, Clark J, Jhavar S, Kovacs G, Cooper CS. Expression analysis onto microarrays of randomly selected cDNA clones highlights HOXB13 as a marker of human prostate cancer. Br J Cancer. 2005;92:376–81. doi: 10.1038/sj.bjc.6602261. [DOI] [PMC free article] [PubMed] [Google Scholar]

[b101] 101.Reid JF, Lusa L, de Cecco L, Coradini D, Veneroni S, Daidone MG, Gariboldi M, Pierotti MA. Limits of predictive models using microarray data for breast cancer clinical treatment outcome. J Natl Cancer Inst. 2005;97:927–30. doi: 10.1093/jnci/dji153. [DOI] [PubMed] [Google Scholar]

[b102] 102.Narla G, Heath KE, Reeves HL, Li D, Giono LE, Kimmelman AC, Glucksman MJ, Narla J, Eng FJ, Chan AM, Ferrari AC, Martignetti JA, Friedman SL. KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science. 2001;294:2563–6. doi: 10.1126/science.1066326. [DOI] [PubMed] [Google Scholar]

[b103] 103.Chen C, Hyytinen ER, Sun X, Helin HJ, Koivisto PA, Frierson HF, Jr, Vessella RL, Dong JT. Deletion, mutation, and loss of expression of KLF6 in human prostate cancer. Am J Pathol. 2003;162:1349–54. doi: 10.1016/S0002-9440(10)63930-2. [DOI] [PMC free article] [PubMed] [Google Scholar]

[b104] 104.Muhlbauer KR, Grone HJ, Ernst T, Grone E, Tschada R, Hergenhahn M, Hollstein M. Analysis of human prostate cancers and cell lines for mutations in the TP53 and KLF6 tumour suppressor genes. Br J Cancer. 2003;89:687–90. doi: 10.1038/sj.bjc.6601164. [DOI] [PMC free article] [PubMed] [Google Scholar]

[b105] 105.Narla G, Difeo A, Reeves HL, Schaid DJ, Hirshfeld J, Hod E, Katz A, Isaacs WB, Hebbring S, Komiya A, McDonnell SK, Wiley KE, Jacobsen SJ, Isaacs SD, Walsh PC, Zheng SL, Chang BL, Friedrichsen DM, Stanford JL, Ostrander EA, Chinnaiyan AM, Rubin MA, Xu J, Thibodeau SN, Friedman SL, Martignetti JA. A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res. 2005;65:1213–22. doi: 10.1158/0008-5472.CAN-04-4249. [DOI] [PubMed] [Google Scholar]

[b106] 106.Li D, Yea S, Dolios G, Martignetti JA, Narla G, Wang R, Walsh MJ, Friedman SL. Regulation of Kruppel-like factor 6 tumor suppressor activity by acetylation. Cancer Res. 2005;65:9216–25. doi: 10.1158/0008-5472.CAN-05-1040. [DOI] [PubMed] [Google Scholar]

[b107] 107.Chen C, Bhalala HV, Vessella RL, Dong JT. KLF5 is frequently deleted and down-regulated but rarely mutated in prostate cancer. Prostate. 2003;55:81–8. doi: 10.1002/pros.10205. [DOI] [PubMed] [Google Scholar]

[b108] 108.Sun X, Frierson HF, Chen C, Li C, Ran Q, Otto KB, Cantarel BL, Vessella RL, Gao AC, Petros J, Miura Y, Simons JW, Dong JT. Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer. Nat Genet. 2005;37:407–12. doi: 10.1038/ng1528. [DOI] [PubMed] [Google Scholar]

[b109] 109.Alipov G, Nakayama T, Ito M, Kawai K, Naito S, Nakashima M, Niino D, Sekine I. Overexpression of Ets-1 proto-oncogene in latent and clinical prostatic carcinomas. Histopathology. 2005;46:202–8. doi: 10.1111/j.1365-2559.2005.02059.x. [DOI] [PubMed] [Google Scholar]

[b110] 110.Thelen P, Jarry H, Ringert RH, Wuttke W. Silibinin down-regulates prostate epithelium-derived Ets transcription factor in LNCaP prostate cancer cells. Planta Med. 2004;70:397–400. doi: 10.1055/s-2004-818965. [DOI] [PubMed] [Google Scholar]

[b111] 111.Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644–8. doi: 10.1126/science.1117679. [DOI] [PubMed] [Google Scholar]

[b112] 112.Isaacs JT. The biology of hormone refractory prostate cancer. Why does it develop. Urol Clin North Am. 1999;26:263–73. doi: 10.1016/s0094-0143(05)70066-5. [DOI] [PubMed] [Google Scholar]

[b113] 113.Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature. 2004;432:332–7. doi: 10.1038/nature03096. [DOI] [PMC free article] [PubMed] [Google Scholar]

[b114] 114.Micke P, Ostman A. Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy. Lung Cancer. 2004;45(Suppl 2):S163–75. doi: 10.1016/j.lungcan.2004.07.977. [DOI] [PubMed] [Google Scholar]

[b115] 115.Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999;59:5002–11. doi: 10.1186/bcr138. [DOI] [PMC free article] [PubMed] [Google Scholar]

[b116] 116.Hayward SW, Wang Y, Cao M, Hom YK, Zhang B, Grossfeld GD, Sudilovsky D, Cunha GR. Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Res. 2001;61:8135–42. [PubMed] [Google Scholar]

[b117] 117.Begley L, Monteleon C, Shah RB, Macdonald JW, Macoska JA. CXCL12 overexpression and secretion by aging fibroblasts enhance human prostate epithelial proliferation in vitro. Aging Cell. 2005;4:291–8. doi: 10.1111/j.1474-9726.2005.00173.x. [DOI] [PubMed] [Google Scholar]

[b118] 118.Rothhammer T, Hahne JC, Florin A, Poser I, Soncin F, Wernert N, Bosserhoff AK. The Ets-1 transcription factor is involved in the development and invasion of malignant melanoma. Cell Mol Life Sci. 2004;61:118–28. doi: 10.1007/s00018-003-3337-8. [DOI] [PMC free article] [PubMed] [Google Scholar]

[b119] 119.Hahne JC, Okuducu AF, Kaminski A, Florin A, Soncin F, Wernert N. Ets-1 expression promotes epithelial cell transformation by inducing migration, invasion and anchorage-independent growth. Oncogene. 2005;24:5384–8. doi: 10.1038/sj.onc.1208761. [DOI] [PubMed] [Google Scholar]

[b120] 120.Wernert N, Okuducu AF, Pepper MS. Ets 1 is expressed in capillary blood vessels but not in lymphatics. J Pathol. 2003;200:561–7. doi: 10.1002/path.1380. [DOI] [PubMed] [Google Scholar]

[b121] 121.Hill R, Song Y, Cardiff RD, Van Dyke T. Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell. 2005;123:1001–11. doi: 10.1016/j.cell.2005.09.030. [DOI] [PubMed] [Google Scholar]

[b122] 122.Koeneman KS, Yeung F, Chung LW. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate. 1999;39:246–1. doi: 10.1002/(sici)1097-0045(19990601)39:4<246::aid-pros5>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]

[b123] 123.Chung LW, Baseman A, Assikis V, Zhau HE. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol. 2005;173:10–20. doi: 10.1097/01.ju.0000141582.15218.10. [DOI] [PubMed] [Google Scholar]

[b124] 124.Koutsilieris M, van Ta R, Diblalexi D, Pitulis N, Sotiriou E, Lembessis P, Bogdanos J, Milathianakis C, Sourla A. Bone metastasis microenvironment participates in the development of androgen ablation refractoriness and chemotherapy resistance of prostate cancer cells residing in the skeleton: clinical implications. In: Meadows GG, editor. Integration/interaction of oncogenic growth. Springer; 2005. pp. 335–44. editor. . Dordrecht: [Google Scholar]

[b125] 125.Djakiew D. Dysregulated expression of growth factors and their receptors in the development of prostate cancer. Prostate. 2000;42:150–60. doi: 10.1002/(sici)1097-0045(20000201)42:2<150::aid-pros10>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]

[b126] 126.van der Poel HG. Smart drugs in prostate cancer. Eur Urol. 2004;45:1–17. doi: 10.1016/j.eururo.2003.08.011. [DOI] [PubMed] [Google Scholar]

[b127] 127.Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP, Guenther MG, Kumar RM, Murray HL, Jenner RG, Gifford DK, Melton DA, Jaenisch R, Young RA. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell. 2005;122:947–56. doi: 10.1016/j.cell.2005.08.020. [DOI] [PMC free article] [PubMed] [Google Scholar]

[b128] 128.Chew JL, Loh YH, Zhang W, Chen X, Tam WL, Yeap LS, Li P, Ang YS, Lim B, Robson P, Ng HH. Reciprocal transcriptional regulation of Pou5f1 and Sox2 via the Oct4/Sox2 complex in embryonic stem cells. Mol Cell Biol. 2005;25:6031–46. doi: 10.1128/MCB.25.14.6031-6046.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]

[b129] 129.Miller SJ, Lavker RM, Sun TT. Interpreting epithelial cancer biology in the context of stem cells: tumor properties and therapeutic implications. Biochim Biophys Acta. 2005;1756:25–52. doi: 10.1016/j.bbcan.2005.07.003. [DOI] [PubMed] [Google Scholar]

[b130] 130.Beachy PA, Karhadkar SS, Berman DM. Tissue repair and stem cell renewal in carcinogenesis. Nature. 2004;432:324–31. doi: 10.1038/nature03100. [DOI] [PubMed] [Google Scholar]

[b131] 131.Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005;434:843–50. doi: 10.1038/nature03319. [DOI] [PubMed] [Google Scholar]

[b132] 132.Karhadkar SS, Bova GS, Abdallah N, Dhara S, Gardner D, Maitra A, Isaacs JT, Berman DM, Beachy PA. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature. 2004;431:707–12. doi: 10.1038/nature02962. [DOI] [PubMed] [Google Scholar]

[b133] 133.Fan L, Pepicelli CV, Dibble CC, Catbagan W, Zarycki JL, Laciak R, Gipp J, Shaw A, Lamm ML, Munoz A, Lipinski R, Thrasher JB, Bushman W. Hedgehog signaling promotes prostate xenograft tumor growth. Endocrinology. 2004;145:3961–70. doi: 10.1210/en.2004-0079. [DOI] [PubMed] [Google Scholar]

[b134] 134.Sanchez P, Hernandez AM, Stecca B, Kahler AJ, de Gueme AM, Barrett A, Beyna M, Datta MW, Datta S, Altaba A. Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOGGLI1 signaling. Proc Natl Acad Sci USA. 2004;101:12561–6. doi: 10.1073/pnas.0404956101. [DOI] [PMC free article] [PubMed] [Google Scholar]

[b135] 135.Sheng T, Li C, Zhang X, Chi S, He N, Chen K, McCormick F, Gatalica Z, Xie J. Activation of the hedgehog pathway in advanced prostate cancer. Mol Cancer. 2004;3:29. doi: 10.1186/1476-4598-3-29. [DOI] [PMC free article] [PubMed] [Google Scholar]

[b136] 136.Podlasek CA, Barnett DH, Clemens JQ, Bak PM, Bushman W. Prostate development requires Sonic hedgehog expressed by the urogenital sinus epithelium. Dev Biol. 1999;209:28–39. doi: 10.1006/dbio.1999.9229. [DOI] [PubMed] [Google Scholar]

[b137] 137.Barnett DH, Huang HY, Wu XR, Laciak R, Shapiro E, Bushman W. The human prostate expresses sonic hedgehog during fetal development. J Urol. 2002;168:2206–10. doi: 10.1016/S0022-5347(05)64356-X. [DOI] [PubMed] [Google Scholar]

[b138] 138.Freestone SH, Marker P, Grace OC, Tomlinson DC, Cunha GR, Harnden P, Thomson AA. Sonic hedgehog regulates prostatic growth and epithelial differentiation. Dev Biol. 2003;264:352–62. doi: 10.1016/j.ydbio.2003.08.018. [DOI] [PubMed] [Google Scholar]

[b139] 139.Sanchez P, Clement V, Altaba A. Therapeutic targeting of the Hedgehog-GLI pathway in prostate cancer. Cancer Res. 2005;65:2990–2. doi: 10.1158/0008-5472.CAN-05-0439. [DOI] [PubMed] [Google Scholar]

[b140] 140.Kuzmichev A, Margueron R, Vaquero A, Preissner TS, Scher M, Kirmizis A, Ouyang X, Brockdorff N, Abate-Shen C, Farnham P, Reinberg D. Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc Natl Acad Sci USA. 2005;102:1859–64. doi: 10.1073/pnas.0409875102. [DOI] [PMC free article] [PubMed] [Google Scholar]

[b141] 141.Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature. 2003;423:255–60. doi: 10.1038/nature01572. [DOI] [PubMed] [Google Scholar]

[b142] 142.Dimri GP, Martinez JL, Jacobs JJ, Keblusek P, Itahana K, Van Lohuizen M, Campisi J, Wazer DE, Band V. The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. Cancer Res. 2002;62:4736–45. [PubMed] [Google Scholar]

[b143] 143.Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest. 2005;115:1503–21. doi: 10.1172/JCI23412. [DOI] [PMC free article] [PubMed] [Google Scholar]

[b144] 144.Hudson DL. Epithelial stem cells in human prostate growth and disease. Prostate Cancer Prostatic Dis. 2004;7:188–94. doi: 10.1038/sj.pcan.4500745. [DOI] [PubMed] [Google Scholar]

[b145] 145.Peehl DM. Primary cell cultures as models of prostate cancer development. Endocr Relat Cancer. 2005;12:19–47. doi: 10.1677/erc.1.00795. [DOI] [PubMed] [Google Scholar]

[b146] 146.Maitland NJ, Collins A. A tumour stem cell hypothesis for the origins of prostate cancer. BJU Int. 2005;96:1219–23. doi: 10.1111/j.1464-410X.2005.05744.x. [DOI] [PubMed] [Google Scholar]

[b147] 147.Burger PE, Xiong X, Coetzee S, Salm SN, Moscatelli D, Goto K, Wilson EL. Sca-1 expression identifies stem cells in the proximal region of prostatic ducts with high capacity to reconstitute prostatic tissue. Proc Natl Acad Sci USA. 2005;102:7180–5. doi: 10.1073/pnas.0502761102. [DOI] [PMC free article] [PubMed] [Google Scholar]

[b148] 148.Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci. 2004;117:3539–45. doi: 10.1242/jcs.01222. [DOI] [PubMed] [Google Scholar]

[b149] 149.Xin L, Lawson DA, Witte ON. The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. Proc Natl Acad Sci USA. 2005;102:6942–7. doi: 10.1073/pnas.0502320102. [DOI] [PMC free article] [PubMed] [Google Scholar]

[b150] 150.Kurita T, Medina RT, Mills AA, Cunha GR. Role of p63 and basal cells in the prostate. Development. 2004;131:4955–64. doi: 10.1242/dev.01384. [DOI] [PubMed] [Google Scholar]

[b151] 151.Signoretti S, Pires MM, Lindauer M, Horner JW, Grisanzio C, Dhar S, Majumder P, McKeon F, Kantoff PW, Sellers WR, Loda M. p63 regulates commitment to the prostate cell lineage. Proc Natl Acad Sci USA. 2005;102:11355–60. doi: 10.1073/pnas.0500165102. [DOI] [PMC free article] [PubMed] [Google Scholar]

[b152] 152.Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, Wahl M, Nisitani S, Yamashiro J, Le Beau MM, Loda M, Witte ON. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA. 1998;95:1735–40. doi: 10.1073/pnas.95.4.1735. [DOI] [PMC free article] [PubMed] [Google Scholar]

[b153] 153.Tran CP, Lin C, Yamashiro J, Reiter RE. Prostate stem cell antigen is a marker of late intermediate prostate epithelial cells. Mol Cancer Res. 2002;1:113–21. [PubMed] [Google Scholar]

[b154] 154.Lam JS, Yamashiro J, Shintaku IP, Vessella RL, Jenkins RB, Horvath S, Said JW, Reiter RE. Prostate stem cell antigen is overexpressed in prostate cancer metastases. Clin Cancer Res. 2005;11:2591–6. doi: 10.1158/1078-0432.CCR-04-1842. [DOI] [PubMed] [Google Scholar]

[b155] 155.Van Leenders GJ, Gage WR, Hicks JL, Van Balken B, Aalders TW, Schalken JA, de Marzo AM. Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy. Am J Pathol. 2003;162:1529–37. doi: 10.1016/S0002-9440(10)64286-1. [DOI] [PMC free article] [PubMed] [Google Scholar]

[b156] 156.Epstein JI. Diagnosis and reporting of limited adenocarcinoma of the prostate on needle biopsy. Mod Pathol. 2004;17:307–15. doi: 10.1038/modpathol.3800050. [DOI] [PubMed] [Google Scholar]

[b157] 157.Enokida H, Shiina H, Igawa M, Ogishima T, Kawakami T, Bassett WW, Anast JW, Li LC, Urakami S, Terashima M, Verma M, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R. CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer. Cancer Res. 2004;64:5956–62. doi: 10.1158/0008-5472.CAN-04-0081. [DOI] [PubMed] [Google Scholar]

[b158] 158.Lou W, Krill D, Dhir R, Becich MJ, Dong JT, Frierson HF, Jr, Isaacs WB, Isaacs JT, Gao AC. Methylation of the CD44 metastasis suppressor gene in human prostate cancer. Cancer Res. 1999;59:2329–31. [PubMed] [Google Scholar]

[b159] 159.Verkaik NS, Van Steenbrugge GJ, Van Weerden WM, Bussemakers MJ, van der Kwast TH. Silencing of CD44 expression in prostate cancer by hypermethylation of the CD44 promoter region. Lab Invest. 2000;80:1291–8. doi: 10.1038/labinvest.3780137. [DOI] [PubMed] [Google Scholar]

[b160] 160.Kito H, Suzuki H, Ichikawa T, Sekita N, Kamiya N, Akakura K, Igarashi T, Nakayama T, Watanabe M, Harigaya K, Ito H. Hypermethylation of the CD44 gene is associated with progression and metastasis of human prostate cancer. Prostate. 2001;49:110–5. doi: 10.1002/pros.1124. [DOI] [PubMed] [Google Scholar]

[b161] 161.Reiter RE, Sato I, Thomas G, Qian J, Gu Z, Watabe T, Loda M, Jenkins RB. Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer. Genes Chromosomes Cancer. 2000;27:95–103. doi: 10.1002/(sici)1098-2264(200001)27:1<95::aid-gcc12>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]

[b162] 162.Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005;65:10946–51. doi: 10.1158/0008-5472.CAN-05-2018. [DOI] [PubMed] [Google Scholar]

[b163] 163.Ohlsson R, Kanduri C, Whitehead J, Pfeifer S, Lobanenkov V, Feinberg AP. Epigenetic variability and the evolution of human cancer. Adv Cancer Res. 2003;88:145–68. doi: 10.1016/s0065-230x(03)88306-9. [DOI] [PubMed] [Google Scholar]

[b164] 164.Kallakury BV, Sheehan CE, Winn-Deen E, Oliver J, Fisher HA, Kaufman RP, Jr, Ross JS. Decreased expression of catenins (alpha and beta), p120 CTN, and E-cadherin cell adhesion proteins and E-cadherin gene promoter methylation in prostatic adenocarcinomas. Cancer. 2001;92:2786–95. doi: 10.1002/1097-0142(20011201)92:11<2786::aid-cncr10128>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]

[b165] 165.Lai JS, Brown LG, True LD, Hawley SJ, Etzioni RB, Higano CS, Ho SM, Vessella RL, Corey E. Metastases of prostate cancer express estrogen receptor-β. Urology. 2004;64:814–20. doi: 10.1016/j.urology.2004.05.036. [DOI] [PubMed] [Google Scholar]

[b166] 166.Zhu X, Leav I, Leung YK, Wu M, Liu Q, Gao Y, McNeal JE, Ho SM. Dynamic regulation of estrogen receptor-β expression by DNA methylation during prostate cancer development and metastasis. Am J Pathol. 2004;164:2003–12. doi: 10.1016/s0002-9440(10)63760-1. [DOI] [PMC free article] [PubMed] [Google Scholar]

[b167] 167.Yang G, Truong LD, Timme TL, Ren C, Wheeler TM, Park SH, Nasu Y, Bangma CH, Kattan MW, Scardino PT, Thompson TC. Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res. 1998;4:1873–80. [PubMed] [Google Scholar]

[b168] 168.Cui J, Rohr LR, Swanson G, Speights VO, Maxwell T, Brothman AR. Hypermethylation of the caveolin-1 gene promoter in prostate cancer. Prostate. 2001;46:249–56. doi: 10.1002/1097-0045(20010215)46:3<249::aid-pros1030>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]

[b169] 169.Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM. Delineation of prognostic biomarkers in prostate cancer. Nature. 2001;412:822–6. doi: 10.1038/35090585. [DOI] [PubMed] [Google Scholar]

[b170] 170.Magee JA, Araki T, Patil S, Ehrig T, True L, Humphrey PA, Catalona WJ, Watson MA, Milbrandt J. Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res. 2001;61:5692–6. [PubMed] [Google Scholar]

[b171] 171.Stephan C, Yousef GM, Scorilas A, Jung K, Jung M, Kristiansen G, Hauptmann S, Kishi T, Nakamura T, Loening SA, Diamandis EP. Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer. J Urol. 2004;171:187–91. doi: 10.1097/01.ju.0000101622.74236.94. [DOI] [PubMed] [Google Scholar]

[b172] 172.Srikantan V, Valladares M, Rhim JS, Moul JW, Srivastava S. HEPSIN inhibits cell growth/invasion in prostate cancer cells. Cancer Res. 2002;62:6812–6. [PubMed] [Google Scholar]

[b173] 173.Klezovitch O, Chevillet J, Mirosevich J, Roberts RL, Matusik RJ, Vasioukhin V. Hepsin promotes prostate cancer progression and metastasis. Cancer Cell. 2004;6:185–95. doi: 10.1016/j.ccr.2004.07.008. [DOI] [PubMed] [Google Scholar]

[b174] 174.Wong AK, Shanahan F, Chen Y, Lian L, Ha P, Hendricks K, Ghaffari S, Iliev D, Penn B, Woodland AM, Smith R, Salada G, Carillo A, Laity K, Gupte J, Swedlund B, Tavtigian SV, van Gan DH, Lees E. BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines. Cancer Res. 2000;60:6171–7. [PubMed] [Google Scholar]

[b175] 175.Valdman A, Nordenskjold A, Fang X, Naito A, Al Shukri S, Larsson C, Ekman P, Li C. Mutation analysis of the BRG1 gene in prostate cancer clinical samples. Int J Oncol. 2003;22:1003–7. [PubMed] [Google Scholar]

[b176] 176.Filippova GN, Qi CF, Ulmer JE, Moore JM, Ward MD, Hu YJ, Loukinov DI, Pugacheva EM, Klenova EM, Grundy PE, Feinberg AP, Cleton-Jansen AM, Moerland EW, Cornelisse CJ, Suzuki H, Komiya A, Lindblom A, Dorion-Bonnet F, Neiman PE, Morse HC, III, Collins SJ, Lobanenkov VV. Tumor-associated zinc finger mutations in the CTCF transcription factor selectively alter its DNA-binding specificity. Cancer Res. 2002;62:48–52. [PubMed] [Google Scholar]

[b177] 177.Hong JA, Kang Y, Abdullaev Z, Flanagan PT, Pack SD, Fischette MR, Adnani MT, Loukinov DI, Vatolin S, Risinger JI, Custer M, Chen GA, Zhao M, Nguyen DM, Barrett JC, Lobanenkov VV, Schrump DS. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Cancer Res. 2005;65:7763–74. doi: 10.1158/0008-5472.CAN-05-0823. [DOI] [PubMed] [Google Scholar]

[b178] 178.Tamimi Y, van der Poel HG, de Nyn MM, Umbas R, Karthaus HF, de Bruyne FM, Schalken JA. Increased expression of high mobility group protein I(Y) in high grade prostatic cancer determined by in situ hybridization. Cancer Res. 1993;53:5512–6. [PubMed] [Google Scholar]

[b179] 179.Katoh M. Expression of human SOX7 in normal tissues and tumors. Int J Mol Med. 2002;9:363–8. [PubMed] [Google Scholar]

PERMALINK

Epigenetics of prostate cancer: beyond DNA methylation

W A Schulz

J Hatina

Abstract

References

ACTIONS

PERMALINK

RESOURCES

Cite

Add to Collections

PERMALINK

Epigenetics of prostate cancer: beyond DNA methylation

W A Schulz

J Hatina

Abstract

References

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases